Caroline Robert

Q: What Schools Are Affiliated With Caroline Robert

Caroline Robert is affiliated with the following schools: University of Sydney, University of Oxford, Université Paris Cité, Aix-Marseille University, McGill University, Yale University, Paris-Saclay University, Université du Québec, University of Louisville, Massachusetts Institute of Technology, University of Tübingen, Sorbonne University

Caroline Robert's AcademicInfluence.com Rankings

Caroline Robert

Biology

#3455

World Rank

#5284

Historical Rank

Molecular Biology

#231

World Rank

#235

Historical Rank

Biochemistry

#324

World Rank

#393

Historical Rank

biology Degrees

Download Badge

Biology

Caroline Robert's Degrees

PhD Biology Université Paris Cité

Why Is Caroline Robert Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Caroline Robert's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Initial sequencing and analysis of the human genome. (2001) (15222)
Improved survival with ipilimumab in patients with metastatic melanoma. (2010) (13093)
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
PD-1 blockade induces responses by inhibiting adaptive immune resistance (2014) (4971)
Nivolumab in previously untreated melanoma without BRAF mutation. (2015) (4628)
Pembrolizumab versus Ipilimumab in Advanced Melanoma. (2015) (4517)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (2011) (4157)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. (2013) (3189)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. (2015) (2383)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota (2015) (2213)
Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) (2115)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. (2015) (1773)
Improved survival with MEK inhibition in BRAF-mutated melanoma. (2012) (1601)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016) (1560)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial (2014) (1524)
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014) (1496)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. (2015) (1348)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (2017) (1274)
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012) (1230)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018) (1137)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. (2006) (1133)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (1102)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (2015) (1097)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. (2016) (1048)
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial (2005) (979)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (2015) (978)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma (2017) (964)
Microbial culturomics: paradigm shift in the human gut microbiome study. (2012) (909)
Genome sequence of the plant pathogen Ralstonia solanacearum (2002) (896)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) (2017) (883)
The 1.2-Megabase Genome Sequence of Mimivirus (2004) (845)
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner (2005) (836)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. (2016) (831)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. (2012) (819)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) (806)
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study (2006) (767)
Comparative Genomics of Multidrug Resistance in Acinetobacter baumannii (2006) (765)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (2017) (755)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination (2016) (741)
A Giant Virus in Amoebae (2003) (730)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. (2016) (730)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. (2016) (710)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (706)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (2019) (692)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma (2014) (691)
Culture of previously uncultured members of the human gut microbiota by culturomics (2016) (691)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. (2019) (606)
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. (2018) (603)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients (2013) (595)
A decade of immune-checkpoint inhibitors in cancer therapy (2020) (584)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (2018) (577)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. (2016) (572)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. (2009) (541)
Cutaneous side-effects of kinase inhibitors and blocking antibodies. (2005) (537)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. (2016) (506)
The virophage as a unique parasite of the giant mimivirus (2008) (498)
Inflammatory skin diseases, T cells, and immune surveillance. (1999) (473)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. (2016) (468)
Genome sequence of the cyanobacterium Prochlorococcus marinus SS120, a nearly minimal oxyphototrophic genome (2003) (465)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2017) (462)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. (2017) (459)
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma (2011) (459)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. (2019) (451)
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology (2017) (421)
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. (2015) (416)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network (2013) (411)
The complete genome sequence of Lactobacillus bulgaricus reveals extensive and ongoing reductive evolution. (2006) (405)
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. (2018) (372)
Unique features revealed by the genome sequence of Acinetobacter sp. ADP1, a versatile and naturally transformation competent bacterium. (2004) (354)
Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα (2009) (351)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. (2017) (344)
Giant Marseillevirus highlights the role of amoebae as a melting pot in emergence of chimeric microorganisms (2009) (337)
Comparative Analysis of Acinetobacters: Three Genomes for Three Lifestyles (2008) (322)
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. (2008) (315)
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. (2017) (310)
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. (2004) (309)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. (2017) (308)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019) (307)
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. (2007) (306)
MHC Class I-Related Neonatal Fc Receptor for IgG Is Functionally Expressed in Monocytes, Intestinal Macrophages, and Dendritic Cells1 (2001) (301)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial (2020) (300)
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. (2012) (298)
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies (2014) (296)
Genome Sequence of Rickettsia bellii Illuminates the Role of Amoebae in Gene Exchanges between Intracellular Pathogens (2006) (293)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. (2013) (283)
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. (2016) (270)
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma (2013) (265)
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report (2020) (257)
Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma (2011) (254)
The Genome Sequence of Rickettsia felis Identifies the First Putative Conjugative Plasmid in an Obligate Intracellular Parasite (2005) (249)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016) (243)
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. (2012) (241)
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. (2007) (235)
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. (2016) (234)
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. (2017) (229)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (2019) (228)
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma (2010) (225)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial (2019) (224)
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. (2008) (223)
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. (2018) (222)
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. (2017) (213)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo (2020) (212)
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). (2011) (210)
Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). (2011) (210)
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. (2012) (206)
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. (2015) (206)
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. (2008) (206)
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. (2011) (205)
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. (2018) (205)
Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. (2000) (203)
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. (2013) (199)
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab (2018) (195)
Provirophages and transpovirons as the diverse mobilome of giant viruses (2012) (195)
New drugs in melanoma: it's a whole new world. (2011) (194)
Interaction of Dendritic Cells with Skin Endothelium: A New Perspective on Immunosurveillance (1999) (194)
Cutaneous melanoma (2014) (188)
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. (2013) (186)
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. (2012) (185)
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. (1999) (185)
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. (2013) (185)
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. (2009) (185)
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. (2016) (184)
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. (2015) (183)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial (2019) (181)
High-level colonisation of the human gut by Verrucomicrobia following broad-spectrum antibiotic treatment. (2013) (177)
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma (2018) (176)
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. (2009) (175)
A panoramic view of gene expression in the human kidney (2003) (174)
Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome. (2003) (173)
Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib (2009) (172)
Reductive Genome Evolution from the Mother of Rickettsia (2007) (171)
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study (2017) (169)
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. (2008) (168)
Corrections to "Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (166)
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. (2014) (164)
Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . (2012) (163)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. (2015) (159)
Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era (2006) (159)
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study (2019) (156)
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer (2020) (156)
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. (2013) (153)
Dermatologic symptoms associated with the multikinase inhibitor sorafenib. (2009) (152)
Kidney injuries related to ipilimumab (2014) (151)
The Genome of Borrelia recurrentis, the Agent of Deadly Louse-Borne Relapsing Fever, Is a Degraded Subset of Tick-Borne Borrelia duttonii (2008) (150)
Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma (2007) (149)
Enterocolitis due to immune checkpoint inhibitors: a systematic review (2018) (147)
Survival of patients with advanced metastatic melanoma: The impact of novel therapies. (2016) (146)
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control (2013) (145)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (145)
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. (2019) (144)
Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner (2017) (143)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. (2020) (143)
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (2017) (141)
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma (2018) (140)
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). (2014) (140)
Increased Gut Redox and Depletion of Anaerobic and Methanogenic Prokaryotes in Severe Acute Malnutrition (2016) (139)
Systemic Therapy for Melanoma: ASCO Guideline. (2020) (137)
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. (2017) (135)
Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1 (2011) (132)
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. (2011) (132)
Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors (2018) (131)
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. (2017) (131)
The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics (2013) (129)
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. (2008) (128)
What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? (2009) (128)
Mimivirus shows dramatic genome reduction after intraamoebal culture (2011) (126)
RAF inhibition and induction of cutaneous squamous cell carcinoma (2011) (124)
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials (2017) (124)
Analysis of the Rickettsia africae genome reveals that virulence acquisition in Rickettsia species may be explained by genome reduction (2009) (123)
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. (2018) (123)
Nail toxicities induced by systemic anticancer treatments. (2015) (122)
First isolation of Mimivirus in a patient with pneumonia. (2013) (122)
Cutaneous side‐effects in patients on long‐term treatment with epidermal growth factor receptor inhibitors (2009) (121)
Prognostic factors of paraneoplastic pemphigus. (2012) (121)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) (119)
Lateral gene transfer between obligate intracellular bacteria: evidence from the Rickettsia massiliae genome. (2007) (118)
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial (2020) (116)
Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample (2013) (115)
Related Giant Viruses in Distant Locations and Different Habitats: Acanthamoeba polyphaga moumouvirus Represents a Third Lineage of the Mimiviridae That Is Close to the Megavirus Lineage (2012) (115)
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) (2018) (114)
Sequence and analysis of chromosome 3 of the plant Arabidopsis thaliana. (2000) (114)
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-α be better? (2005) (113)
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities (2017) (112)
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. (2013) (111)
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. (2020) (110)
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma (2017) (110)
The rhizome of the multidrug-resistant Enterobacter aerogenes genome reveals how new "killer bugs" are created because of a sympatric lifestyle. (2013) (109)
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab? (2008) (108)
Non contiguous-finished genome sequence and description of Peptoniphilus timonensis sp. nov. (2012) (107)
Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases (2012) (106)
Erratum: Initial sequencing and analysis of the human genome: International Human Genome Sequencing Consortium (Nature (2001) 409 (860-921)) (2001) (106)
Clostridium butyricum Strains and Dysbiosis Linked to Necrotizing Enterocolitis in Preterm Neonates. (2015) (105)
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. (2016) (104)
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. (2019) (103)
Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). (2009) (103)
Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. (2014) (103)
Viruses in the desert: a metagenomic survey of viral communities in four perennial ponds of the Mauritanian Sahara (2012) (102)
Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. (2016) (101)
Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma (2004) (101)
Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. (2015) (100)
Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. (2002) (99)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (97)
Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics (2020) (96)
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. (2021) (96)
Prediction of cervical cancer recurrence using textural features extracted from 18F-FDG PET images acquired with different scanners (2017) (94)
Marseillevirus-like virus recovered from blood donated by asymptomatic humans. (2013) (93)
Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. (2012) (91)
A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. (2004) (91)
Persistent Cancer Cells: The Deadly Survivors (2020) (91)
Gut Bacteria Missing in Severe Acute Malnutrition, Can We Identify Potential Probiotics by Culturomics? (2017) (91)
Use of Genome Selected Repeated Sequences Increases the Sensitivity of PCR Detection of Tropheryma whipplei (2004) (91)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (90)
Vemurafenib and radiosensitization. (2013) (90)
A Metagenomic Investigation of the Duodenal Microbiota Reveals Links with Obesity (2015) (90)
Non-contiguous finished genome sequence and description of Herbaspirillum massiliense sp. nov. (2012) (89)
Viruses with More Than 1,000 Genes: Mamavirus, a New Acanthamoeba polyphaga mimivirus Strain, and Reannotation of Mimivirus Genes (2011) (89)
Small molecules and targeted therapies in distant metastatic disease (2009) (88)
Samba virus: a novel mimivirus from a giant rain forest, the Brazilian Amazon (2014) (88)
Non-contiguous finished genome sequence and description of Clostridium dakarense sp. nov. (2013) (87)
Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. (2015) (87)
Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing (2009) (87)
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. (2013) (86)
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. (2016) (86)
Non-contiguous finished genome sequence and description of Clostridium senegalense sp. nov. (2012) (86)
4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. (2018) (86)
Analysis of the lacZ sequences from two Streptococcus thermophilus strains: comparison with the Escherichia coli and Lactobacillus bulgaricus beta-galactosidase sequences. (1991) (85)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial (2022) (85)
Non contiguous-finished genome sequence and description of Enterobacter massiliensis sp. nov. (2013) (84)
Renal effects of immune checkpoint inhibitors (2016) (83)
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study (2016) (83)
Comparison of the gut microbiota of people in France and Saudi Arabia (2015) (82)
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006 (2018) (81)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (81)
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. (2014) (81)
Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. (1997) (80)
ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee. (2020) (79)
Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation (2018) (79)
Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion (2017) (79)
Non-contiguous finished genome sequence and description of Alistipes ihumii sp. nov. (2012) (79)
Sequence of the pig major histocompatibility region containing the classical class I genes (2001) (78)
Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031) (2008) (77)
Non-contiguous finished genome sequence and description of Brevibacterium senegalense sp. nov. (2012) (77)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. (2018) (77)
The DNA sequence and analysis of human chromosome 14 (2003) (76)
Genome Analysis of Minibacterium massiliensis Highlights the Convergent Evolution of Water-Living Bacteria (2007) (76)
Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma (2007) (76)
Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics (2019) (76)
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. (2015) (74)
Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma (2007) (74)
Complete Genome Sequence of Methanomassiliicoccus luminyensis, the Largest Genome of a Human-Associated Archaea Species (2012) (74)
Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients (2008) (73)
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. (2017) (73)
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. (2015) (72)
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? (2005) (72)
ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. (2008) (72)
Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status. (2017) (71)
Safety and efficacy of vemurafenib in BRAF V 600 E and BRAF V 600 K mutation-positive melanoma ( BRIM-3 ) : extended follow-up of a phase 3 , randomised , open-label study (2015) (71)
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma (2020) (70)
Non-contiguous finished genome sequence and description of Kurthia massiliensis sp. nov. (2012) (70)
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma (2016) (70)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. (2016) (70)
Radiomics in Nuclear Medicine Applied to Radiation Therapy: Methods, Pitfalls, and Challenges. (2018) (69)
Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. (2016) (69)
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. (2020) (68)
Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses (2008) (68)
New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis (2015) (68)
Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. (2016) (67)
Genome sequence and description of Alistipes senegalensis sp. nov. (2012) (67)
Culturomics and pyrosequencing evidence of the reduction in gut microbiota diversity in patients with broad-spectrum antibiotics. (2014) (65)
Severe meningo-radiculo-nevritis associated with ipilimumab (2012) (65)
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. (2016) (65)
Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment (2016) (64)
Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. (2001) (64)
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. (2017) (64)
Kaumoebavirus, a New Virus That Clusters with Faustoviruses and Asfarviridae (2016) (64)
Real-Time Sequencing To Decipher the Molecular Mechanism of Resistance of a Clinical Pan-Drug-Resistant Acinetobacter baumannii Isolate from Marseille, France (2012) (64)
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? (2005) (64)
The new era of adjuvant therapies for melanoma (2018) (64)
Genomic Exploration of the Hemiascomycetous Yeasts: 11. Kluyveromyces lactis (2000) (64)
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. (2020) (63)
Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. (2018) (63)
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies (2017) (63)
The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features (2019) (61)
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. (2015) (61)
Tyrosine kinase inhibition and grey hair (2003) (61)
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i (2020) (59)
Genomic, proteomic, and transcriptomic analysis of virulent and avirulent Rickettsia prowazekii reveals its adaptive mutation capabilities. (2010) (59)
Phylogenomic Analysis of Odyssella thessalonicensis Fortifies the Common Origin of Rickettsiales, Pelagibacter ubique and Reclimonas americana Mitochondrion (2011) (58)
Electrochemotherapy: a new treatment of solid tumors. (2003) (58)
Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. (2013) (58)
Molecular Studies Neglect Apparently Gram-Negative Populations in the Human Gut Microbiota (2013) (57)
LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial (2020) (57)
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. (2014) (57)
Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas (2015) (56)
Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. (2013) (56)
Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. (2017) (56)
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. (2019) (55)
Conjugative mobilization as an alternative vector delivery system for lactic streptococci (1987) (55)
Gut microbiota associated with HIV infection is significantly enriched in bacteria tolerant to oxygen (2016) (55)
Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies (2013) (55)
Tumour burden and efficacy of immune-checkpoint inhibitors (2021) (54)
Immune checkpoint inhibitors (2021) (54)
Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma (2010) (54)
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. (2016) (54)
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. (2017) (54)
Targeted therapy-induced radiation recall. (2013) (52)
Advances in the management of cutaneous toxicities of targeted therapies. (2012) (51)
Identification of human herpesvirus 6 variants A and B by amplimer hybridization with variant-specific oligonucleotides and amplification with variant-specific primers (1994) (51)
Repertoire of the gut microbiota from stomach to colon using culturomics and next-generation sequencing (2018) (50)
Two cases of immune thrombocytopenia associated with pembrolizumab. (2016) (50)
Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. (2019) (50)
Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas (2008) (50)
Gut microbiome and dietary patterns in different Saudi populations and monkeys (2016) (50)
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) (49)
Insight into cross-talk between intra-amoebal pathogens (2011) (49)
[Hypopigmented mycosis fungoides]. (1995) (48)
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. (2019) (48)
Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis (2020) (48)
Conditional suicide system of Escherichia coli released into soil that uses the Bacillus subtilis sacB gene (1993) (48)
Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases (2018) (47)
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (46)
Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? (2012) (46)
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey (2018) (46)
Management and outcome of metastatic melanoma during pregnancy (2010) (46)
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. (2012) (46)
Treponema species enrich the gut microbiota of traditional rural populations but are absent from urban individuals (2018) (44)
Non contiguous-finished genome sequence and description of Peptoniphilus grossensis sp. nov. (2012) (44)
Rapid comparative genomic analysis for clinical microbiology: the Francisella tularensis paradigm. (2008) (44)
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. (2014) (44)
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. (2014) (44)
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4 (2020) (44)
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm (2020) (42)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2019) (42)
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (42)
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. (2014) (42)
Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma (2017) (41)
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies (2011) (41)
Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome (2014) (41)
Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. (2022) (41)
Polyphasic Analysis of a Middle Ages Coprolite Microbiota, Belgium (2014) (41)
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma (2019) (40)
Variations of Plasmid Content in Rickettsia felis (2008) (40)
Glycans affect DNA extraction and induce substantial differences in gut metagenomic studies (2016) (40)
Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors (2014) (40)
Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition. (2019) (40)
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. (2012) (39)
Salt in stools is associated with obesity, gut halophilic microbiota and Akkermansia muciniphila depletion in humans (2018) (39)
[Breast cancer in the early stage]. (2012) (39)
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. (2017) (39)
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma (2022) (39)
mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study (2014) (39)
Non contiguous-finished genome sequence and description of Peptoniphilus obesi sp. nov. (2013) (38)
An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells (2019) (38)
Genome Sequence of Coxiella burnetii 109, a Doxycycline-Resistant Clinical Isolate (2012) (38)
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma (2020) (38)
Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. (2015) (38)
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. (2021) (38)
New Era in the Management of Melanoma Brain Metastases. (2018) (38)
ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee. (2020) (38)
Correlation of Phenotype/Genotype in a Cohort of 23 Xeroderma Pigmentosum‐Variant Patients Reveals 12 New Disease‐Causing POLH Mutations (2014) (37)
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. (2019) (37)
Prevalence of sunbed use, and characteristics and knowledge of sunbed users: results from the French population‐based Edifice Melanoma survey (2015) (37)
Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. (2019) (37)
Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. (2016) (37)
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2020) (37)
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. (2017) (37)
Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. (2011) (37)
Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 (2017) (37)
Nævus éruptifs sous sorafénib (2008) (37)
The plasticity of mRNA translation during cancer progression and therapy resistance (2021) (36)
535PENCORAFENIB (LGX818), AN ORAL BRAF INHIBITOR, IN PATIENTS (PTS) WITH BRAF V600E METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF DOSE EXPANSION IN AN OPEN-LABEL, PHASE 1 STUDY. (2014) (36)
U-ReSNet: Ultimate Coupling of Registration and Segmentation with Deep Nets (2019) (36)
Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. (2020) (36)
Non-contiguous finished genome sequence and description of Bacillus massiliogorillae sp. nov. (2013) (36)
Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature. (2013) (35)
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. (2020) (35)
Bullous Amyloidosis: Report of 3 Cases and Review of the Literature (1993) (35)
Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1 (2018) (35)
Malignant melanoma and granulomatosis (1997) (35)
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. (2014) (35)
5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. (2018) (35)
P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma (2015) (35)
Effets secondaires cutanés du sorafenib et du sunitinib (2008) (34)
Characterization of Viral Communities of Biting Midges and Identification of Novel Thogotovirus Species and Rhabdovirus Genus (2016) (34)
Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. (2014) (34)
Evidence of Transfer by Conjugation of Type IV Secretion System Genes between Bartonella Species and Rhizobium radiobacter in Amoeba (2010) (34)
Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study (2018) (33)
Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients. (2019) (33)
Comparison of a Modern and Fossil Pithovirus Reveals Its Genetic Conservation and Evolution (2016) (33)
Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL). (2014) (33)
Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386) (2018) (33)
Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes (2008) (33)
Brain tumor segmentation with self-ensembled, deeply-supervised 3D U-net neural networks: a BraTS 2020 challenge solution (2020) (33)
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. (2020) (33)
Intratumoral Immunotherapy: From Trial Design to Clinical Practice (2020) (32)
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. (2011) (32)
The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I. (2019) (32)
Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells (2020) (32)
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era (2020) (32)
A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab (Ipi) in patients (pts) with metastatic melanoma (2016) (32)
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. (2016) (31)
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (2011) (31)
Gap Junction Communication between Autologous Endothelial and Tumor Cells Induce Cross-Recognition and Elimination by Specific CTL1 (2009) (31)
Divergent Gemycircularvirus in HIV-Positive Blood, France (2015) (31)
Genome sequence and description of Timonella senegalensis gen. nov., sp. nov., a new member of the suborder Micrococcinae (2013) (31)
Gene therapy to target dendritic cells from blood to lymph nodes (2003) (30)
Draft genome of Gemmata massiliana sp. nov, a water-borne Planctomycetes species exhibiting two variants (2015) (30)
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (2020) (30)
LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES (2014) (30)
Whole-genome assembly of Akkermansia muciniphila sequenced directly from human stool (2015) (30)
Report on the status of women occupying leadership roles in oncology (2018) (30)
Imaging of melanoma: usefulness of ultrasonography before and after contrast injection for diagnosis and early evaluation of treatment (2011) (30)
Difference in permissiveness of human fibroblast cells to variants A and B of human herpesvirus-6. (1996) (29)
Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) (2012) (29)
Update on the role of ipilimumab in melanoma and first data on new combination therapies (2013) (29)
Phase I/II study of 3TC (lamivudine) in HIV‐positive, asymptomatic or mild AIDS‐related complex patients: sustained reduction in viral markers (1995) (29)
[Cutaneous side effects of sorafenib and sunitinib]. (2008) (28)
Pan-genomic analysis to redefine species and subspecies based on quantum discontinuous variation: the Klebsiella paradigm (2015) (28)
Melanoma in 2011: A new paradigm tumor for drug development (2012) (28)
Isolation and characterization of Kingella negevensis sp. nov., a novel Kingella species detected in a healthy paediatric population. (2017) (28)
Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. (2013) (28)
A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer (2018) (28)
Non-contiguous finished genome sequence and description of Bacillus massilioanorexius sp. nov. (2013) (28)
Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction? (2016) (28)
Rickettsia felis, from Culture to Genome Sequencing (2005) (28)
CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. (2010) (27)
Self‐medication in pain management: The state of the art of pharmacists’ role for optimal Over‐The‐Counter analgesic use (2019) (27)
Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma (2016) (27)
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover (2020) (27)
Complete Genome Sequence of Borrelia crocidurae (2012) (27)
Host-Associated Metagenomics: A Guide to Generating Infectious RNA Viromes (2015) (27)
Is earlier better for melanoma checkpoint blockade? (2018) (27)
Pan-Genome Analysis of Brazilian Lineage A Amoebal Mimiviruses (2015) (26)
[Eruptive nevi associated with sorafenib treatment]. (2008) (26)
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. (2019) (26)
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee (2020) (26)
Non-contiguous finished genome sequence and description of Kallipyga massiliensis gen. nov., sp. nov., a new member of the family Clostridiales Incertae Sedis XI (2013) (26)
The genome of Coxiella burnetii Z3055, a clone linked to the Netherlands Q fever outbreaks, provides evidence for the role of drift in the emergence of epidemic clones. (2014) (26)
Non-contiguous finished genome sequence and description of Oceanobacillus massiliensis sp. nov. (2013) (26)
An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma (2007) (26)
Context Aware 3D CNNs for Brain Tumor Segmentation (2018) (26)
Non contiguous-finished genome sequence and description of Clostridium jeddahense sp. nov. (2014) (25)
Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. (2009) (25)
Arterial thrombosis and anti-PD-1 blockade. (2017) (25)
Deep Learning-Based Concurrent Brain Registration and Tumor Segmentation (2020) (24)
Microvirga massiliensis sp. nov., the human commensal with the largest genome (2016) (24)
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. (2019) (24)
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. (2020) (24)
Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. (2017) (24)
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma (2019) (24)
Faustovirus-Like Asfarvirus in Hematophagous Biting Midges and Their Vertebrate Hosts (2015) (24)
Draft genome sequences of Terra1 and Terra2 viruses, new members of the family Mimiviridae isolated from soil. (2014) (24)
The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study. (2016) (24)
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. (2021) (24)
Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) (2021) (24)
Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors (2010) (24)
Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. (2019) (24)
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee (2020) (23)
Detection of antibodies to human herpesvirus-6 using immunofluorescence assay. (1990) (23)
Fournierella massiliensis gen. nov., sp. nov., a new human-associated member of the family Ruminococcaceae. (2017) (23)
Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. (2015) (23)
Non-contiguous finished genome sequence and description of Bartonella florenciae sp. nov. (2013) (23)
Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (2011) (23)
Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site (2014) (23)
Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). (2016) (23)
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. (2018) (23)
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis (2020) (22)
Low Doses of Radiation Increase the Immunosuppressive Profile of Lung Macrophages During Viral Infection and Pneumonia (2020) (22)
Genomic analysis of three African strains of Bacillus anthracis demonstrates that they are part of the clonal expansion of an exclusively pathogenic bacterium (2014) (22)
Melanoma: Smart therapeutic strategies in immuno-oncology (2014) (22)
Anomalies pigmentaires induites par les traitements anticancéreux. Première partie : les chimiothérapies (2013) (22)
Homology between a 173-kb region from mouse chromosome 10, telomeric to the Ifng locus, and human chromosome 12q15. (2001) (22)
Phase I clinical trial combining imatinib mesylate and IL-2 (2013) (22)
Mechanisms of skin aging induced by EGFR inhibitors (2016) (22)
Detection of novel RNA viruses from free-living gorillas, Republic of the Congo: genetic diversity of picobirnaviruses (2018) (22)
Complete genome sequence of Courdo11 virus, a member of the family Mimiviridae (2014) (22)
Loss of Ambra1 promotes melanoma growth and invasion (2021) (22)
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis (2016) (22)
Herpesvirus 6 infection in young children. (1992) (22)
Non-contiguous finished genome sequence and description of Bartonella senegalensis sp. nov. (2013) (22)
Effets cutanés des nouvelles molécules utilisées en cancérologie (2009) (22)
Redox activation of ATM enhances GSNOR translation to sustain mitophagy and tolerance to oxidative stress (2020) (22)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. (2019) (22)
Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3 (2017) (21)
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. (2020) (21)
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? (2017) (21)
Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma. (2017) (21)
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM). (2012) (21)
Anomalies pigmentaires induites par les traitements anticancéreux. Deuxième partie : les thérapies ciblées (2013) (21)
Successful repetitive treatments by electrochemotherapy of multiple unresectable Kaposi sarcoma nodules (2006) (21)
Development of an efficient spheroplast transformation procedure for S. thermophilus: the use of transfection to define a regeneration medium. (1988) (20)
Staphylococcus aureus subsp. anaerobius strain ST1464 genome sequence (2013) (20)
The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy (2012) (20)
The proof of concept that culturomics can be superior to metagenomics to study atypical stool samples (2013) (20)
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives (2020) (20)
A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma (2008) (20)
Relationships between Regional Radiation Doses and Cognitive Decline in Children Treated with Cranio-Spinal Irradiation for Posterior Fossa Tumors (2017) (20)
Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL) (2016) (20)
Reinventing Radiation Therapy with Machine Learning and Imaging Bio-markers (Radiomics): state-of-the-art, challenges and perspectives. (2020) (19)
Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. (2015) (19)
Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. (2021) (19)
Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study (2020) (19)
Effets secondaires cutanés des molécules anti-angiogéniques (2007) (19)
Anticorps anti-CTLA-4 : Une avancée thérapeutique majeure dans le traitement du mélanome métastatique (2011) (18)
Impact of COVID-19 on healthcare organisation and cancer outcomes (2021) (18)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) (18)
Cutaneous malignant melanoma in children and adolescents treated in pediatric oncology units (2016) (18)
Non-contiguous finished genome sequence and description of Anaerococcus vaginalis (2012) (18)
Comparison of sun protection modalities in parents and children (2015) (17)
Genome sequence of Oceanobacillus picturae strain S1, an halophilic bacterium first isolated in human gut (2015) (17)
Rise of Microbial Culturomics: Noncontiguous Finished Genome Sequence and Description of Beduini massiliensis gen. nov., sp. nov. (2015) (17)
Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. (2021) (17)
LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA (2014) (17)
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. (2011) (17)
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
Adjuvant Pembrolizumab in Resected Stage III Melanoma. (2018) (16)
Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. (2013) (16)
Recommandations pour le diagnostic de prédisposition génétique au mélanome cutané et pour la prise en charge des personnes à risque (2015) (16)
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD. (2020) (16)
Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma. (2010) (16)
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. (2021) (16)
Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover (2016) (16)
1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone (2017) (16)
Non-contiguous finished genome sequence and description of Fenollaria massiliensis gen. nov., sp. nov., a new genus of anaerobic bacterium (2014) (16)
Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. (2019) (16)
Sun exposure profile in the French population. Results of the EDIFICE Melanoma survey (2015) (16)
Pregnancy and melanoma: a European‐wide survey to assess current management and a critical literature overview (2017) (16)
Who benefits most from adjuvant interferon treatment for melanoma? (2015) (16)
Microbial Culturomics to Map Halophilic Bacterium in Human Gut: Genome Sequence and Description of Oceanobacillus jeddahense sp. nov. (2016) (16)
HIV-negative patient with HHV-8 DNA follicular B-cell lymphoma associated with Kaposi's sarcoma (1996) (15)
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors (2010) (15)
Microbial Culturomics Broadens Human Vaginal Flora Diversity: Genome Sequence and Description of Prevotella lascolaii sp. nov. Isolated from a Patient with Bacterial Vaginosis. (2018) (15)
Noncontiguous finished genome sequence and description of Virgibacillus massiliensis sp. nov., a moderately halophilic bacterium isolated from human gut (2015) (15)
Yersinia pestis halotolerance illuminates plague reservoirs (2017) (15)
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. (2016) (15)
Genome Sequence of Rickettsia conorii subsp. indica, the Agent of Indian Tick Typhus (2012) (15)
In Regard to Mattonen et al. (2016) (15)
Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC) (2014) (15)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. (2019) (15)
Draft Genome Sequence of a Human-Associated Isolate of Methanobrevibacter arboriphilicus, the Lowest-G+C-Content Archaeon (2014) (14)
Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma. (2020) (14)
Do immune checkpoint inhibitors perform identically in patients with weight extremes? (2018) (14)
Impact des toxicités cutanées associées aux thérapies ciblées sur la qualité de vie. Résultats d’une étude pilote longitudinale (2013) (14)
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. (2022) (14)
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. (2018) (14)
Imagerie médicale computationnelle (radiomique) et potentiel en immuno-oncologie (2017) (14)
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. (2022) (13)
Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy (2019) (13)
Melanoma and other skin tumors (2012) (13)
Draft genome sequence of Coxiella burnetii Dog Utad, a strain isolated from a dog-related outbreak of Q fever (2014) (13)
Melanoma and immunotherapy bridge 2015 (2016) (13)
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial (2022) (13)
Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024 (2012) (13)
Draft Genome Sequencing of Methanobrevibacter oralis Strain JMR01, Isolated from the Human Intestinal Microbiota (2014) (13)
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy (2021) (13)
Interventional Radiology for Local Immunotherapy in Oncology (2021) (13)
Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. (2018) (13)
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. (2019) (13)
Longitudinal subungual acanthoma: one denomination for various clinical presentations (2018) (12)
Deciphering Genomic Virulence Traits of a Staphylococcus epidermidis Strain Causing Native-Valve Endocarditis (2013) (12)
Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031). (2011) (12)
Genome Sequence of Diplorickettsia massiliensis, an Emerging Ixodes ricinus-Associated Human Pathogen (2012) (12)
Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i (2018) (12)
Dosimetry-driven quality measure of brain pseudo Computed Tomography generated from deep learning for MRI-only radiotherapy treatment planning. (2020) (12)
Treatment Algorithms in Stage IV Melanoma (2015) (12)
[Pigmentary disorders induced by anticancer agents. part I: chemotherapy]. (2013) (12)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (2019) (12)
Impact of dermatologic adverse events induced by targeted therapies on quality of life. (2016) (12)
Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". (2018) (12)
Genome Sequence of Microbacterium yannicii, a Bacterium Isolated from a Cystic Fibrosis Patient (2012) (12)
LAG-3 and PD-1 blockade raises the bar for melanoma (2021) (12)
Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL) (2016) (12)
Non-contiguous finished genome sequence and description of Gorillibacterium massiliense gen. nov, sp. nov., a new member of the family Paenibacillaceae (2014) (12)
Comparison of the gut microbiota of obese individuals from different geographic origins (2018) (12)
Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone (2016) (12)
Complete Genome Sequence of Rickettsia slovaca, the Agent of Tick-Borne Lymphadenitis (2012) (12)
Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. (2015) (11)
Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma (2015) (11)
[Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma]. (2015) (11)
Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? (2014) (11)
Characterization of a novel Gram‐stain‐positive anaerobic coccus isolated from the female genital tract: Genome sequence and description of Murdochiella vaginalis sp. nov. (2018) (11)
Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). (2018) (11)
Noncontiguous finished genome sequence and description of Paenibacillus ihumii sp. nov. strain AT5 (2016) (11)
Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial. (2019) (11)
Sentinel lymph node biopsy in cutaneous head and neck melanoma (2018) (11)
The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force (2020) (11)
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (2022) (11)
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature (2017) (11)
P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade. (2017) (11)
Letter to Dermatology (1999) (11)
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules (2021) (11)
Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial. (2020) (11)
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) (2022) (10)
Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines (2016) (10)
Sorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US) (2007) (10)
‘Cellulomonas timonensis’ sp. nov., taxonogenomics description of a new bacterial species isolated from human gut (2018) (10)
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab (2018) (10)
Genome Sequence of “Rickettsia sibirica subsp. mongolitimonae” (2012) (10)
EDIFICE Melanoma survey: knowledge and attitudes on melanoma prevention and diagnosis (2015) (10)
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients (2013) (10)
How cutaneous eruptions help to understand the mode of action of kinase inhibitors (2012) (10)
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study (2018) (10)
[Impact of cutaneous toxicities associated with targeted therapies on quality of life. Results of a longitudinal exploratory study]. (2013) (10)
Non-contiguous finished genome sequence and description of Halopiger djelfamassiliensis sp. nov. (2013) (10)
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma. (2018) (10)
1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (10)
Description of Gabonibacter massiliensis gen. nov., sp. nov., a New Member of the Family Porphyromonadaceae Isolated from the Human Gut Microbiota (2016) (10)
High-quality genome sequence and description of Bacillus dielmoensis strain FF4T sp. nov. (2015) (10)
Partial Disruption of Translational and Posttranslational Machinery Reshapes Growth Rates of Bartonella birtlesii (2013) (10)
A haplotype map of the human genome The International HapMap Consortium (2005) (10)
Genome Sequence of Rickettsia conorii subsp. israelensis, the Agent of Israeli Spotted Fever (2012) (10)
Saudi Moumouvirus, the First Group B Mimivirus Isolated from Asia (2016) (10)
Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase III study (CheckMate 066). (2015) (10)
Low doses of radiation therapy increase the immunosuppressive profile of lung macrophages via IL-10 production and IFNγ/IL-6 suppression: a therapeutic strategy to counteract lung inflammation? (2020) (10)
Noncontiguous finished genome sequence and description of Gabonia massiliensis gen. nov., sp. nov. (2015) (10)
Genomic Comparison of Rickettsia helvetica and Other Rickettsia Species (2012) (10)
Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study (2019) (10)
Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase II study (CheckMate 069). (2015) (10)
One or Two Immune Checkpoint Inhibitors? (2019) (10)
The multiple roles of LDH in cancer (2022) (10)
Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. (2019) (9)
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. (2014) (9)
Top 10 BraTS 2020 challenge solution: Brain tumor segmentation with self-ensembled, deeply-supervised 3D-Unet like neural networks (2020) (9)
Evolution of sun‐protection measures for children (2015) (9)
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma (2022) (9)
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. (2017) (9)
Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies (2017) (9)
Genome Sequence of Rickettsia australis, the Agent of Queensland Tick Typhus (2012) (9)
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial (2020) (9)
Non-contiguous finished genome sequence and description of Corynebacterium jeddahense sp. nov. (2014) (9)
Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification. (2018) (9)
Deep Learning Based Registration Using Spatial Gradients and Noisy Segmentation Labels (2020) (9)
Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: Results of a prospective study. (2004) (9)
Non-contiguous finished genome sequence and description of Clostridium saudii sp. nov (2014) (9)
Virgibacillus senegalensis sp. nov., a new moderately halophilic bacterium isolated from human gut (2015) (9)
Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor (2013) (9)
[Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]. (2011) (9)
Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs) (2021) (9)
Regulation of CD 4 + NKG 2 D + Th 1 cells in patients with metastatic melanoma treated with Sorafenib : role of IL-15 R α and NKG 2 D triggering (2013) (9)
1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone (2020) (9)
Management of Sentinel-Node Metastasis in Melanoma. (2018) (9)
Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI) (2020) (9)
Risk-based stratification in head and neck mucosal melanoma. (2019) (9)
Breast cancer following radiotherapy for a hemangioma during childhood (2010) (9)
Melanoma during fingolimod treatment for multiple sclerosis. (2019) (9)
Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. (2021) (9)
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies]. (2013) (9)
Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3. (2011) (9)
Draft Genome Sequence of Kingella negevensis SW7208426, the First European Strain of K. negevensis Isolated from a Healthy Child in Switzerland (2017) (9)
melanoma and other skin tumoursIpilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial (2016) (8)
Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA). (2011) (8)
Human pegivirus isolates characterized by deep sequencing from hepatitis C virus‐RNA and human immunodeficiency virus‐RNA–positive blood donations, France (2018) (8)
Sequence and Annotation of Rickettsia sibirica sibirica Genome (2012) (8)
Noncontiguous finished genome sequence and description of Planococcus massiliensis sp. nov., a moderately halophilic bacterium isolated from the human gut (2015) (8)
The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. (2020) (8)
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. (2022) (8)
Mélanome vaginal : une localisation particulièrement défavorable (2012) (8)
Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy. (2017) (8)
A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status (2013) (8)
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. (2020) (8)
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma. (2022) (8)
High-quality genome sequence and description of Paenibacillus dakarensis sp. nov. (2016) (8)
Non-contiguous finished genome sequence and description of Kurthia senegalensis sp. nov. (2014) (8)
ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy. (2019) (8)
Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. (2021) (8)
Radiotherapy as a risk factor for malignant melanoma after childhood skin hemangioma (2012) (8)
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006 (2021) (8)
Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study. (2012) (8)
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. (2021) (8)
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. (2020) (8)
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL). (2013) (8)
LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs) (2020) (8)
A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy. (2013) (8)
COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM). (2017) (8)
Genomic Comparison of Rickettsia honei Strain RBT and Other Rickettsia Species (2012) (8)
Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: A retrospective multicentric French study. (2017) (8)
Genome Sequence of Legionella anisa, Isolated from a Respiratory Sample, Using an Amoebal Coculture Procedure (2014) (8)
Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511. (2021) (7)
Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group. (1995) (7)
[Epithelial and melanic skin tumours]. (2007) (7)
Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. (2018) (7)
Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. (2021) (7)
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials (2021) (7)
Can radiation-recall predict long lasting response to immune checkpoint inhibitors? (2020) (7)
baumannii Isolate from Marseille, France Clinical Pan-Drug-Resistant Acinetobacter Molecular Mechanism of Resistance of a Real-Time Sequencing To Decipher the (2014) (7)
Genome Sequence of Reyranella massiliensis, a Bacterium Associated with Amoebae (2012) (7)
Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma (2017) (7)
Draft Genome Sequence of Brevibacterium massiliense Strain 541308T (2012) (7)
Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients withBRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial (2020) (7)
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples (2014) (7)
BRAF +/- MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006 (2018) (7)
[Mechanisms of resistance to anti-BRAF treatments]. (2014) (7)
PH-0532: Standardization of brain MRI across machines and protocols: bridging the gap for MRI-based radiomics (2020) (7)
FC13 DERMA Phase III trial of MAGE-A3 immunotherapy as adjuvant treatment in stage III melanoma: MAGE-A3 gene expression frequency and baseline demographics (2010) (7)
Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis. (2020) (7)
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. (2022) (7)
Genome Sequence of the Tick-Borne Pathogen Rickettsia raoultii (2016) (7)
Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019 (2021) (7)
[Immunotherapies and melanoma]. (2014) (7)
Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study. (2020) (7)
Genome Sequence of Bacillus simplex Strain P558, Isolated from a Human Fecal Sample (2014) (7)
Asymmetric Acral Spared Phenomenon Related to Systemic Anticancer Therapies (2018) (7)
Genome Sequence of Rickettsia conorii subsp. caspia, the Agent of Astrakhan Fever (2012) (7)
Développement et comparaison de méthodes d'assimilation de données de rang réduit dans un modèle de circulation océanique : application à l'océan Pacifique Tropical (2004) (7)
[Human herpesvirus-6 infection and hepatitis following heart transplantation]. (1994) (7)
Mécanismes de résistance aux inhibiteurs de BRAF (2014) (7)
Genome Sequence of Rickettsia gravesii, Isolated from Western Australian Ticks (2013) (6)
Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma. (2015) (6)
[Cancers of the skin, relations to ultraviolet rays]. (1995) (6)
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus. (2021) (6)
Non-contiguous finished genome sequence and description of Anaerococcus provenciensis sp. nov. (2014) (6)
Gastrointestinal Immune Related Adverse Events Associated with Programmed-Death 1 Blockade (2017) (6)
Non-contiguous finished genome sequence and description of Anaerococcus pacaensis sp. nov., a new species of anaerobic bacterium (2013) (6)
Draft Genome Sequence of Actinomyces massiliensis Strain 4401292T (2012) (6)
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. (2021) (6)
Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. (2016) (6)
Non contiguous-finished genome sequence and description of Enorma timonensis sp. nov. (2014) (6)
Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial (2011) (6)
LBA46 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial (2020) (6)
Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma. (2019) (6)
Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. (2019) (6)
[Malignant melanoma of the vagina: pejorative location]. (2012) (6)
Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial (2020) (6)
Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002. (2015) (6)
Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (2017) (6)
Draft Genome Sequence of Coxiella burnetii Strain Cb196, an Agent of Endocarditis in Saudi Arabia (2014) (6)
Genome sequence of Rickettsia bellii Illuminates the Role of Ancestral Protozoa in Gene Exchanges Between Intracellular Pathogens (2005) (6)
Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma (2020) (6)
Cutaneous Reaction to Ultraviolet Irradiation in Human-Immunodeficiency-Virus-Infected Patients (1999) (6)
Des avancées thérapeutiques majeures dans le traitement du mélanome métastatique (2012) (6)
Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma (2019) (6)
Drancourtella massiliensis gen. nov., sp. nov. isolated from fresh healthy human faecal sample from South France (2016) (6)
Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8+ T lymphocyte emergence (2013) (6)
Complete genome sequence and description of Lactococcus garvieae M14 isolated from Algerian fermented milk (2016) (6)
Phase I/II study of the association of sorafenib and temozolomide (extended schedule) in patients with metastatic melanoma: A new clinical response profile with massive tumor necroses. (2009) (5)
Multi-spacer typing as an effective method to distinguish the clonal lineage of Clostridium butyricum strains isolated from stool samples during a series of necrotizing enterocolitis cases. (2017) (5)
Non-contiguous finished genome sequence and description of Bacteroides neonati sp. nov., a new species of anaerobic bacterium (2014) (5)
MAP-kinase pathway up or down? Just look at the skin of your patients! (2014) (5)
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. (2022) (5)
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis (2021) (5)
Drug‐induced Nail Changes (2012) (5)
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma (2022) (5)
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. (2021) (5)
Non-contiguous-Finished Genome Sequence and Description of Paenibacillus camerounensis sp. nov. (2016) (5)
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). (2021) (5)
Proof of Concept of Gene Therapy Using Plasmid Amep in Disseminated Melanoma: Safety and Efficacy Results of A Phase I First-In-Man Study (2012) (5)
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma (2022) (5)
[Major therapeutic advances in the treatment of metastatic melanoma]. (2012) (5)
Noncontiguous finished genome sequence and description of Paenibacillus antibioticophila sp. nov. GD11T, the type strain of Paenibacillus antibioticophila (2015) (5)
Genome Sequence of Bartonella birtlesii, a Bacterium Isolated from Small Rodents of the Genus Apodemus (2012) (5)
Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613. (2014) (5)
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study (2021) (5)
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop (2020) (5)
[Computational medical imaging (radiomics) and potential for immuno-oncology]. (2017) (5)
Oceanobacillus timonensis sp. nov. and Oceanobacillus senegalensis sp. nov., two new moderately halophilic, Gram-stain positive bacteria isolated from stools sample of healthy young Senegalese (2018) (5)
Genomic Analysis of Rickettsia japonica Strain YHT (2012) (5)
[Management of recurrent soft tissue sarcoma of the retroperitoneum]. (2004) (5)
1087OEFFICACY, SAFETY, AND QUALITY OF LIFE (QOL) DATA FROM THE EORTC 18071 PHASE III TRIAL OF IPILIMUMAB (IPI) VERSUS PLACEBO AFTER COMPLETE RESECTION OF STAGE III MELANOMA. (2014) (5)
Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors? (2018) (5)
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. (2022) (5)
Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma. (2017) (5)
961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy (2021) (5)
Selection and characterization of two specific monoclonal antibodies directed against the two variants of human herpesvirus-6. (1998) (5)
Seminal vesicle metastasis of cutaneous malignant melanoma: An unusual and challenging presentation. (2015) (5)
140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475) (2014) (5)
[Cutaneous side effects of antiangiogenic agents]. (2007) (5)
Draft Genome Sequence of Mycobacterium houstonense Strain ATCC 49403T (2016) (4)
Prise en charge des effets dermatologiques sous erlotinib. Résultats de l’étude PRECEDE (2009) (4)
Improving Radiotherapy Workflow Through Implementation of Delineation Guidelines & AI-Based Annotation (2020) (4)
Dakarella massiliensis gen. nov., sp. nov., strain ND3T: a new bacterial genus isolated from the female genital tract (2017) (4)
1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study (2020) (4)
Personal vs. intrinsic melanoma risk awareness: results of the EDIFICE Melanoma survey (2015) (4)
Prognostic factors for progression free and overall survival in advanced GIST: Results from the BFR14 phase III trial of the French Sarcoma Group (2005) (4)
Malignant hypercalcemia induced by a parathyroid hormone-related protein secreted by a cutaneous squamous cell carcinoma. (1997) (4)
Bioactive Flavaglines: Synthesis and Pharmacology (2015) (4)
Sentinel lymph node biopsy in 33 non‐melanoma skin cancers of the head and neck: A twelve‐year experience with long‐term follow‐up (2018) (4)
9302 Excellent long-term survival of patients with minimal sentinel node tumor burden (<0.1 mm) according to Rotterdam Criteria: a study of the EORTC melanoma group (2009) (4)
Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial. (2021) (4)
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. (2012) (4)
[Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies]. (2014) (4)
Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. (2021) (4)
Dental pulp as a source of low-contaminated DNA. (2017) (4)
Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective: A real-life analysis. (2018) (4)
Kingella kingae KK247, an Atypical Pulsed-Field Gel Electrophoresis Clone A Strain (2014) (4)
PO-1002 Pseudo Computed Tomography generation using 3D deep learning – Application to brain radiotherapy (2019) (4)
Traitement des récidives des sarcomes rétro-péritonéaux (2004) (4)
Evidence of human herpesvirus 6 in Sjögren syndrome and sarcoidosis (1992) (4)
Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma. (2013) (4)
Genome Sequence of Legionella tunisiensis Strain LegMT, a New Legionella Species Isolated from Hypersaline Lake Water (2012) (4)
Non-contiguous finished genome sequence of Prevotella timonensis type strain 4401737T (2014) (4)
Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review (2019) (4)
Folliculitis and perionyxis associated with the EGFR inhibitor erlotinib (2006) (4)
Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition (2022) (4)
Intensive induction chemotherapy (API-AI regimen) followed by conservative surgery in adult patients with locally advanced soft tissue sarcoma (STS): Survival is predicted by the histological response (2004) (4)
«Veillonella massiliensis», a new anaerobic species isolated from human colostrum (2017) (4)
Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial. (2018) (4)
LBA6_PRCOMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanoma (2017) (4)
Systemic Therapy Options for Patients With Unresectable Melanoma. (2017) (4)
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib (2021) (4)
Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients. (2022) (4)
“Mycobacterium massilipolynesiensis” sp. nov., a rapidly-growing mycobacterium of medical interest related to Mycobacterium phlei (2017) (4)
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. (2022) (4)
Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma. (2014) (4)
Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone (2015) (4)
Genome Sequence of Lactobacillus ingluviei, a Bacterium Associated with Weight Gain in Animals (2012) (4)
Molecular pathology of cutaneous melanoma. (2014) (4)
Exposition aux ultraviolets en cabine : habitudes et pratiques de la population française (2012) (4)
Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis (2021) (4)
Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone. (2010) (4)
Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases (2018) (4)
Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas (2019) (4)
Genome Sequence of Borrelia crocidurae Strain 03-02, a Clinical Isolate from Senegal (2014) (4)
Draft Genome Sequence of Mycobacterium farcinogenes NCTC 10955 (2014) (4)
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (2011) (3)
Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma (2018) (3)
ipilimumab Versus Placebo After Complete Resection Of Stage Iii Melanoma: Efficacy And Safety Results From The Eortc 18071 Phase Iii Trial : 374 (2014) (3)
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. (2022) (3)
Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting (2019) (3)
Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL). (2015) (3)
Bon usage du sorafénib chez les patients pris en charge pour un carcinome hépatocellulaire ou un cancer du rein (2010) (3)
Adverse events of special interest in the phase 3 COLUMBUS study. (2018) (3)
Non-contiguous genome sequence of Mycobacterium simiae strain DSM 44165T (2013) (3)
Draft Genome and Description of Eisenbergiella massiliensis Strain AT11T: A New Species Isolated from Human Feces After Bariatric Surgery (2018) (3)
Draft Genome Sequence of Mycobacterium mucogenicum Strain CSUR P2099 (2015) (3)
Systemic Therapy Options for Patients With Unresectable Melanoma. (2017) (3)
Human pegivirus (HPgV) isolates characterized by deep sequencing from HCV- and HIV-RNA positive blood donations, France (2018) (3)
Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (2018) (3)
Draft Genome Sequence of Mycobacterium vulneris DSM 45247T (2014) (3)
Traitement systémique des métastases cérébrales de mélanome (2015) (3)
Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting (2018) (3)
Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. (2011) (3)
[Use of sorafenib in patients with hepatocellular or renal carcinoma]. (2010) (3)
1047P Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM) (2021) (3)
Non-contiguous finished genome sequence and description of Paenibacillus gorillae sp. nov. (2014) (3)
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C. (2019) (3)
Melanoma risk‐takers: fathers and sons (2015) (3)
Axitinib dans le cancer du rein métastatique: actualisation des connaissances sur la prise en charge des effets secondaires (2014) (3)
Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. (2019) (3)
IgG4 related orbit disease - An unusual cause of an orbital mass. (2018) (3)
The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance (2021) (3)
Erratum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma (Nature (2011) 480:94-98 doi:10.1038/nature10539) (2016) (3)
Quoi de neuf en cancérologie cutanée (2008) (3)
[Sezary syndrome with palmoplantar bullous lesions]. (1992) (3)
Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study. (2022) (3)
BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports. (2019) (3)
1245PQuality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma (2017) (3)
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma (2022) (3)
Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study (2016) (3)
Sediminibacillus massiliensis sp. nov., a moderately halophilic, Gram-positive bacterium isolated from a stool sample of a young Senegalese man (2018) (3)
EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL) (2017) (3)
A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma (2021) (3)
Hypermetabolic dermatofibroma on Positron Emission Tomography/Computed tomography with 18F-FluoroDeoxyGlucose : a misleading false positive in the follow-up of a metastatic melanoma. (2008) (3)
Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma (2022) (3)
A Blinded Prospective Evaluation Of Clinical Applicability Of Deep Learning-Based Auto Contouring Of OAR For Head and Neck Radiotherapy (2020) (3)
Activation of the MAP-kinase pathway in the skin of patients treated with sorafenib: Clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib. (2010) (3)
Draft Genome Sequence of Mycobacterium austroafricanum DSM 44191 (2014) (3)
Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma (2015) (3)
Cutaneous Side Effects of Multikinase Inhibitors Used in Renal Cell Cancer (2007) (3)
A Pooled analysis of 655 patients with advanced melanoma enrolled in keynote-001 : long-term efficacy of pembrolizumab (mk-3475) (2015) (3)
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. (2022) (3)
Genome Sequence of Afipia birgiae, a Rare Bacterium Associated with Amoebae (2012) (3)
[New drugs in oncology and skin toxicity]. (2009) (3)
Noncontiguous Genome Sequence of Mycobacterium septicum Strain DSM 44393T (2013) (3)
1010P Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008 (2021) (3)
Corrections to "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors". (2015) (2)
1032PPROLONGED ANTI-TUMOR ACTIVITY OF LUCITANIB IN ADVANCED THYROID CANCER. (2014) (2)
Les bons comptes font les bons amis (2015) (2)
Draft Genome Sequence of Mycobacterium neoaurum Strain DSM 44074T (2014) (2)
Risungbinella massiliensis sp. nov., a new member of Thermoactinomycetaceae isolated from human gut (2016) (2)
Genome Sequence of Bartonella rattaustraliani, a Bacterium Isolated from an Australian Rat (2012) (2)
Mycobacterium ahvazicum sp. nov., the nineteenth species of the Mycobacterium simiae complex (2018) (2)
Non-contiguous-Finished Genome Sequence and Description of Paenibacillus camerounensis sp. nov. (2015) (2)
Noncontiguous finished genome sequence and description of Nocardioides massiliensis sp. nov. GD13T (2016) (2)
Viruses with more than 1000 genes: Mamavirus, a new Acanthamoeba castellanii mimivirus 3 strain, and reannotation of mimivirus genes 4 5 Short title: Mamavirus, a new Mimivirus strain 6 7 (2011) (2)
Correction: Variations of Plasmid Content in Rickettsia felis (2008) (2)
Draft Genome Sequence of Necropsobacter rosorum Strain P709T (2014) (2)
Draft Genome Sequence of Mycobacterium boenickei CIP 107829 (2017) (2)
9318 POSTER Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma (2011) (2)
Paradoxical cutaneous squamous cell proliferations in patients treated with sorafenib. (2009) (2)
P202 Ipilimumab colitis: a GETAID multicentric study (2014) (2)
Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (2018) (2)
105PBaseline gut microbiota in metastatic melanoma patients treated with ipilimumab: Relation with clinical response and colitis (2017) (2)
Gene Expression High-Dimensional Clustering Towards a Novel, Robust, Clinically Relevant and Highly Compact Cancer Signature (2019) (2)
BRAF and NRAS mutational status in clear cell sarcoma (2005) (2)
Le vice de l’alcool et les discours antialcooliques au tournant du XX siècle québécois (2020) (2)
Neuropathies sensitives sous la combinaison inhibiteurs de BRAF et de MEK : dabrafénib et tramétinib (2016) (2)
Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : thérapies ciblées et effets secondaires dermatologiques (2011) (2)
Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials (2019) (2)
1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma (2021) (2)
A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM). (2018) (2)
Reconnaître et traiter les effets cutanés liés à l'erlotinib (2007) (2)
Fréquence des résistances au vismodegib dans une série de 207 patients atteints de carcinomes basocellulaires localement avancés (2016) (2)
Vismodegib (V), un inhibiteur de la voie Hedgehog (HPI), dans le carcinome basocellulaire avancé (CBCa) : analyse intermédiaire de l’étude STEVIE (2013) (2)
Optimisation de l'architecture HiSens, une nouvelle architecture de gamma-caméra CdZnTe haute sensibilité pour l'imagerie clinique (2010) (2)
Fiabilité des assemblages de puissance (2015) (2)
[Physician-patient relations in dermatology]. (1997) (2)
Abstract 934: BRAF inhibitors induce skin and extra-cutaneous tumors via paradoxical activation of the MAPK pathway: Molecular study of 66 tumors and visualization of BRAF/CRAF protein dimers (2014) (2)
[Management of patients with melanoma]. (2014) (2)
Immunotherapy of Melanoma: A New Era (2011) (2)
Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib. (2014) (2)
Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). (2019) (2)
Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?" (2018) (2)
Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study. (2022) (2)
Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare. (2017) (2)
Pharmacokinetic results of a phase I trial of sorafenib (S) in combination with dacarbazine (DTIC) in patients with advanced metastatic melanoma or other solid tumors (2007) (2)
Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. (2020) (2)
Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma (2015) (2)
Vemurafenib (V) in BRAF V600E metastatic melanoma (mM): Analysis of 507 patients (pts) enrolled in the French temporary authorization for use (ATU). (2012) (2)
Response assessment to anti-CTLA4 or/and anti-PD1 immunotherapy in mucosal melanomas. (2018) (2)
1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma (2020) (2)
Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (2)
Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?" (2019) (2)
277 Safety and efficacy of intratumoral ipilimumab with IV nivolumab in metastatic melanoma. The NIVIPIT trial (2021) (2)
Association of VitiligoWith Tumor Response in Patients WithMetastatic Melanoma TreatedWith Pembrolizumab (2016) (2)
A dose escalation phase 1 study of radiotherapy (RT) in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab in patients (pts) with metastatic melanoma. (2017) (2)
[Axitinib in metastatic renal carcinomas: update of knowledge about side effects]. (2014) (2)
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study (2020) (2)
PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. (2017) (2)
Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma. (2016) (2)
Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. (2018) (2)
Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation? (2019) (2)
105 POSTER A prospective study of the cutaneous side effects of sorafenib, a novel multi-kinase inhibitor (2006) (2)
Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma. (2019) (2)
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma (2022) (2)
Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1 (2022) (2)
1049P Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI) (2021) (2)
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i) (2022) (2)
1224PDAnalysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002 (2017) (2)
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. (2022) (2)
Radiation guidelines for gliomas (2021) (2)
Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. (2022) (2)
Multi-omics prediction in melanoma immunotherapy: A new brick in the wall. (2022) (2)
Study of BRAF mutations in melanoma and nevi from patients with germline mutation in the CDKN2A gene. (2006) (1)
D.S. Mirsky : profil critique et bibliographique (1983) (1)
In situ detection of the eIF4F translation initiation complex in mammalian cells and tissues (2021) (1)
Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). (2019) (1)
Draft Genome Sequence of Mycobacterium lentiflavum CSUR P1491 (2015) (1)
Cancers secondaires sous immunothérapies dans un contexte de mélanome métastatique (2016) (1)
Effect of CTLA-4 blockade on lymphocyte resistance to regulatory T cells in advanced melanoma and use as a surrogate marker of efficacy of tremelimumab (2008) (1)
A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients (pts) with metastatic melanoma: Analysis of peripheral neuropathy. (2013) (1)
871P Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post hoc exploratory analysis from phase III COMBI-i trial (2022) (1)
Prediction of cervical cancer recurrence using textural features calculated from 18F-FDG PET images (2016) (1)
Une approche hybride variationnelle-stochastique pour l'assimilation de données (2007) (1)
Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients with advanced melanoma who progressed on prior anti-programmed cell death-1 (anti-PD-1) therapy. (2020) (1)
Samba virus: a novel mimivirus from a giant rain forest, the Brazilian Amazon (2014) (1)
Severe ototoxicity associated with immune checkpoint inhibitors (ICI) in advanced melanoma. (2022) (1)
Quoi de neuf en oncodermatologie? (2018) (1)
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic (2018) (1)
Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis (2020) (1)
Vemurafenib-associated bullous DRESS syndrome: A very severe cutaneous reaction. (2013) (1)
452 - Long-Term Evolution of Gastritis and Enterocolits Induced by Immunological Checkpoint Inhibitors (2018) (1)
An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma. (2018) (1)
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer (2020) (1)
The use of IRE in the treatment of a locally advanced pancreatic cancer (stage 3) of a pancreatic body/neck tumor (2015) (1)
Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events. (2021) (1)
Biomarqueurs tissulaires des immunothérapies anti-PD-1 dans le mélanome (2017) (1)
Draft Genome Sequence of Mycobacterium peregrinum Strain CSUR P2098 (2015) (1)
[Follicular lymphoma and Kaposi's disease arising successively in the same cutaneous area]. (1990) (1)
Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study. (2022) (1)
Optimisation des propriétés structurale de l'interface GaP/Si et des propriétés électroniques de cellules solaires GaAsPN/GaP pour la fabrication de cellule tandem (2013) (1)
Using genetics to predict toxicity of cancer immunotherapy (2022) (1)
Troponin increase during immunotherapy: Not always myocarditis. (2021) (1)
Melanoma Persister Cells are Tolerant to BRAF/MEK Inhibitors Via ACOX1-Mediated Fatty Acid Oxidation (2020) (1)
Place des anti-PD1 dans la prise en charge des mélanomes cutanés (2016) (1)
Draft Genome Sequence of Mycobacterium tuberculosis Strain MT43, a Representative of the Manu2 Genotype (2015) (1)
[Description of erlotinib-related skin effects management in France. Results of the PRECEDE study]. (2009) (1)
Twenty‐two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson’s disease (2009) (1)
Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy (2022) (1)
819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial (2022) (1)
A novel bi‐allelic loss‐of‐function mutation in STIM1 expands the phenotype of STIM1‐related diseases (2020) (1)
Estimateurs à rétrécisseur du paramètre de position d'une loi à symétrie sphérique (1987) (1)
Draft Genome Sequence of Mycobacterium bohemicum Strain DSM 44277T (2015) (1)
Predictive and Prognostic Value of CT Based Radiomics Signature in Head and Neck Squamous Cell Carcinoma Patients Treated With Concurrent Chemoradiation Therapy or Bioradiation Therapy and Its Added Value to Human Papillomavirus Status (2017) (1)
Reply to E. Hindié and K.R. Hess. (2019) (1)
767O TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY OR RELAPSED MELANOMA IN A PHASE II STUDY OF TREMELIMUMAB (CP-675,206), AN ANTI-CTLA4 MONOCLONAL ANTIBODY (2008) (1)
Abstract PR-1: AGENDA: Results of a randomized, double‐blind phase III trial of dacarbazine with or without Bcl‐2 targeted therapy (oblimersen) in a biomarker‐defined patient population with advanced melanoma (2009) (1)
Degats d'oiseaux, un risque reel sur tournesol (2014) (1)
Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors (2022) (1)
Multiple immune-related toxicities in cancer patients treated with anti-programmed death 1 immunotherapies: a new surrogate marker for clinical trials? (2021) (1)
Action de Cocculine dans le traitement des troubles de stabilisation du regard chez le rat (1997) (1)
Données d’efficacité et de tolérance en vie réelle du cétuximab dans le carcinome épidermoïde cutané avancé : étude nationale rétrospective et multicentrique (2018) (1)
[Bacillary angiomatosis]. (1992) (1)
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006 (2018) (1)
Draft Genome Sequence of Staphylococcus massiliensis Strain 5402776T (2012) (1)
Systemic gut microbial metabolites limit the anti-tumour effect of CTLA-4 blockade in hosts with cancer (2019) (1)
A phase I/II study of a multivalent dendritic cell vaccine in patients with metastatic melanoma (2005) (1)
Genome Sequence of Bartonella rattimassiliensis, a Bacterium Isolated from European Rattus norvegicus (2012) (1)
Efficacy of neoadjuvant therapy with cisplatin, fluorouracil, and cetuximab in locally advanced nonresectable epidermoid skin carcinoma. (2009) (1)
ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy (2019) (1)
Abstract CT087: Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) withBRAFV600E/K-mutant melanoma in the COMBAT trial (2018) (1)
Risk stratification of sentinel node positive melanoma patients defines surgical management and adjuvant therapy treatment considerations (2019) (1)
Draft Genome Sequence of Mycobacterium mageritense DSM 44476T (2014) (1)
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (1)
Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma. (2021) (1)
Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma (2016) (1)
A pharyngeal jaw evolutionary innovation facilitated extinction in Lake Victoria cichlids (2015) (1)
Is it melanoma? Ask my dog! (2020) (1)
Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM) (2019) (1)
Comment gérer au mieux la toxicité des traitements antiangiogéniques (2008) (1)
Adjuvant therapy in stage IIIA melanoma - Authors' reply. (2021) (1)
Analysis of Skin Cancers from Xeroderma Pigmentosum Patients Reveals Heterogeneous UV-Induced Mutational Profiles Shaped by DNA Repair (2022) (1)
Intensive induction chemotherapy (API-AI regimen) followed by conservative surgery in adult patients with locally advanced soft tissue sarcoma (STS): Survival is predicted by the histological response. (2004) (1)
Fibroblastome à cellules géantes de la région scroto-anale chez un garçon de cinq ans traité par chirurgie micrographique et réparation par lambeau perforant postérieur de cuisse (2009) (1)
A radiomic signature based on advanced tumor shape parameters (Spiculated-ness) to predict the outcome of locally advanced (LA) HNSCC patients. (2016) (1)
Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C). (2013) (1)
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases. (2022) (1)
PV-0528: An innovative MRI harmonization method allowing large scale radiomics analysis in glioblastoma (2018) (1)
Dermatologic Side Effects of Systemic Anticancer Therapy (2013) (1)
Combination of Triptorelin with Nivolumab in ICI Resistant Advanced Melanoma (2019) (1)
Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma (2018) (1)
Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma. (2020) (1)
Tumour mutational burden and response to PD-1 inhibitors: An analysis of 89 cases of metastatic melanoma (2019) (1)
Etude de la locomotion du cheval au trot par electromyographie de surface et cinematique (2000) (1)
Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006 (2017) (1)
OC-0394: Pretreatment bone marrow SUVmax in locally advanced cervical cancer: a novel prognostic biomarker? (2018) (1)
An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis (2019) (1)
Albert Memmi, “Portrait du colonisé, précédé du portrait du co... (2011) (1)
BEST OF THE BEST RESEARCH 2016 ABSTRACTS. (2016) (1)
Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair default (Muir‐Torre Syndrome) (2021) (1)
Abstract P1-09-11: A phase Ib study of oral administration of lucitanib in combination with fulvestrant in patients with HR+ metastatic breast cancer (mBC) (2018) (1)
Thyroid and Breast cancers following radiotherapy for a hemangioma during infancy (2008) (1)
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (1)
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial. (2018) (1)
[Management of side effects of targeted therapies in renal cancer: cutaneous side effects]. (2011) (1)
[Necrotic ulcer patch mimicking factitious panniculitis disclosing systemic lupus erythematosus]. (1990) (1)
[Production of knowledge using data collected by associations of patients: The fibromyalgia example]. (2021) (1)
Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T). (2019) (1)
804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial (2022) (1)
Non-contiguous finished genome sequence of Phocaeicola abscessus type strain 7401987T (2013) (1)
Effect ofPatient Characteristics on Performance ofan EnzymeImmunoassay forDetecting Cervical Chlamydia trachomatis Infection (1990) (1)
The price of tumor control (2013) (1)
Draft Genome Sequence of Mycobacterium acapulcensis Strain CSURP1424 (2016) (1)
Genomic Analysis of Burkholderia And Rhodococcus equi Bacteriophages (2011) (1)
Anticancer Therapies (2018) (1)
Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma (Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA.) (2019) (1)
Draft Genome Sequence of Mycobacterium tuberculosis Strain MT11, Which Represents a New Lineage (2015) (1)
Draft Genome Sequence of Tsukamurella sp. Strain 1534 (2012) (1)
Cytopénies immunologiques induites par des anticorps anti-PD-1 ou anti-PD-L1 : une étude observationnelle descriptive (2018) (1)
Visceral lesions occurring during follow‐up of melanoma patients: a true place for other diagnosis than melanoma metastasis (2012) (1)
Small Molecule Multikinase Inhibitors (2013) (1)
Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115. (2022) (1)
Metastatic melanoma: New paradigms of treatment and new toxicities (2013) (1)
Refractive changes during immunotherapy: Think diabetes! (2021) (1)
Description of Gabonibacter massiliensis gen. nov., sp. nov., a New Member of the Family Porphyromonadaceae Isolated from the Human Gut Microbiota (2016) (1)
"Dermoscopic and clinical features of congenital or congenital-type nail matrix nevi: a multicenter prospective cohort study by the International Dermoscopy Society". (2022) (1)
Angiosarcomas: Natural history and prognostic factors from 161 cases in three French institutions (2005) (1)
Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (1)
1092TiP Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02 (2021) (0)
Cutaneous genital complications of antiangiogenic agents. (2009) (0)
Aldous Huxley : « Nuns at luncheon » ou les jeux du Je (1998) (0)
426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma (2020) (0)
Effets secondaires cutanés du vémurafénib : étude prospective de 15 patients (2011) (0)
Discussion à propos de la communication : « Mélanome métastatique, immunothérapie et survie à long terme : où en sommes-nous? »1 (2023) (0)
ONCO-WS-11 Echographie de contraste et metastases vesiculaires de melanomes malins : a propos de quatre cas (2008) (0)
Phase I dose escalation study of pan-histone deacetylase (HDAC) inhibitor abexinostat in combination with cisplatin in patients with advanced non-keratinizing nasopharyngeal carcinoma. (2014) (0)
Traitement par anticorps anti-PD-1 : pembrolizumab (MK-3475) chez 411 patients (pts) atteints de mélanome métastatique (2014) (0)
Tumeurs kératinocytaires induites par activation paradoxale de la voie MAPK sous inhibiteur de BRAF – Étude histologique, génétique, et virologique de 57 tumeurs secondaires (2013) (0)
Frôlements et roulements: interactions des cellules dendritiques avec les endothélium : implication en immunothérapie (2001) (0)
Hyperprogression d’un carcinome épidermoïde cutané et poussée évolutive d’une maladie de Waldenström au cours d’une immunothérapie par anticorps anti-PD1 (2021) (0)
C99 - Association de l’électrochimiothérapie et des oligodéoxynucléotides cpg : vers une nouvelle approche vaccinale du mélanome métastatique (2005) (0)
Impact de l’exposition au méthotrexate sur le pronostic des patients atteints de mélanome métastatique : à propos de 2 observations (2019) (0)
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology (2023) (0)
Pancréatite sous vismodégib : une toxicité rare et méconnue (2018) (0)
Métastase sous-cutanée jugale de mélanome malin (2014) (0)
3032A Activity and safety profile of lucitanib in patients with advanced thymic epithelial tumours (2015) (0)
Domiciliation des cellules dendritiques (2004) (0)
Survie à 3 ans des patients traités pour mélanome métastatique par prembrolizumab (Keynote-001) et devenir des patients en réponse complète☆ (2016) (0)
Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib (2021) (0)
Mélanocytome intrabulbaire traité par bévacizumab (2021) (0)
[What's new in oncodermatology?] (2018) (0)
Tumeurs pédiatriques rares (2010) (0)
Reply to: "Mortality due to immunotherapy related hepatitis". (2018) (0)
Identification et prise en charge des effets indésirables liés aux nouvelles immunothérapies anticancéreuses (2017) (0)
Identification de TBX3 comme nouveau régulateur de l’expression de PDL1 dans le mélanome (2018) (0)
Pembrolizumab Yields Strong Long-Term Survival in Advanced Melanoma (2016) (0)
Mélanome métastatique, immunothérapie et survie à long terme : où en sommes-nous ? (2023) (0)
Transformation maligne d’un nævus congénital après six mois de vemurafenib : un nouveau risque à connaître (2012) (0)
Taux de survie globale à deux ans d’un essai clinique randomisé de phase II évaluant l’association de nivolumab et d’ipilimumab dans le mélanome avancé☆ (2016) (0)
Communication médecins–malades : la situation particulière des consultations d’annonce de mélanome (2012) (0)
Efficacité des biothérapies en vie réelle en Europe : résultats à 12 semaines de l’étude Psoriasis Study of Health Outcomes (PSoHO) (2022) (0)
DRESS syndrome bulleux au vemurafenib (2013) (0)
Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy (2021) (0)
Réponses anti-tumorales induites par une réaction immunitaire dirigée contre le virus SARS-CoV-2 (2021) (0)
Elevated Soluble TNF-Receptor 1 in the Serum of Predementia Subjects with Cerebral Small Vessel Disease (2023) (0)
[Not Available]. (2016) (0)
Les répondeurs complets à l’immunothérapie dans le mélanome avancé : facteurs de risque de rechute et devenir des patients (2021) (0)
Survie sans métastases à distance avec pembrolizumab versus placebo en traitement adjuvant du mélanome de stade IIB ou IIC : étude de phase III KEYNOTE-716 (2022) (0)
Procédé et ensemble caméra pour détecter des gouttes de pluie sur un pare-brise d'un véhicule (2011) (0)
Évolution des mesures de protection solaire pour les enfants en France (2012) (0)
Sun exposure profile in the French population: Results of the EDIFICE melanoma survey. (2012) (0)
Les effets secondaires des thérapies anti B-Raf et leur impact sur la qualité de vie : l’étude Skin Target (2013) (0)
Vice, déviance et criminalité (2020) (0)
Procédé de détection des gouttes de pluie sur un pare-brise de véhicule et dispositif d'aide à la conduite (2010) (0)
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2021) (0)
Deux schémas posologiques de l’association nivolumab (NIVO) plus ipilimumab (IPI) dans le mélanome avancé : résultats à 3 ans de l’étude CheckMate 511 (2021) (0)
Dermatological Complications of Systemic Therapies for Melanoma (2020) (0)
Toxicité gastro-intestinale induite par les inhibiteurs de checkpoint immunitaire de type anticorps anti-CTLA-4 et anti-PD-1/PD-L1 (2018) (0)
Anti-MEK Agents in Perspective (2013) (0)
Immunothérapie néoadjuvante du mélanome dans le contexte de la pandémie COVID-19 (2021) (0)
Granulomatoses associées aux immunothérapies du mélanome (2021) (0)
Panniculite sous inhibiteur de BRAF et MEK (2011) (0)
Réponse rapide et spectaculaire de deux mélanomes desmoplastiques localement avancés au pembrolizumab (2016) (0)
University of Groningen The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node- positive melanoma without the need for completion lymph node dissection Verver, (2020) (0)
Réponse spectaculaire à 1 seule injection de cémiplimab pour un carcinome épidermoïde cutané avec toxicité cardiovasculaire à ne pas méconnaître (2021) (0)
Traduction CAP-dépendante: une nouvelle cible thérapeutique dans le mélanome résistant au vemurafenib (2013) (0)
Efficacité du cétuximab en situation néoadjuvante dans le traitement des carcinomes épidermoïdes cutanés localement avancés inopérables (2013) (0)
Les changements de regard sur les figures géométriques (2012) (0)
Ototoxicité chez 2 patients traités par immunothérapie pour un mélanome métastatique (2021) (0)
Étude d’un algorithme adapté de gestion de la fièvre chez les patients traités par dabrafénib + tramétinib en adjuvant : premiers résultats de la cohorte française de COMBI-APlus (2021) (0)
Caractérisations des atteintes leptoméningées métastatiques au cours du mélanome : un enjeu diagnostique et pronostique (2021) (0)
Caractéristiques et réponses aux traitements dans le mélanome stade III non opérable et stade IV : étude rétrospective longitudinale MELODY (2011) (0)
Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma (2021) (0)
Résultats finaux d’une cohorte de 705 patients atteints de mélanome avancé et ayant débuté un traitement par pembrolizumab au cours de son programme français d’ATU (2021) (0)
Abstract B40: Translational control of tumor immune escape via the eIF4F-STAT1-PDL1 axis in melanoma (2020) (0)
Utilisation des tests génomiques en oncologie : avis d’experts Français selon la méthode Delphi (2023) (0)
Traitement du mélanome métastatique. Gestion de risque (2017) (0)
Genotype characterization and prognosis of unknown primary melanoma patients with nodal metastases. (2012) (0)
Panniculite sous inhibiteur de mTOR (2012) (0)
Procédé de détection du brouillard et des gouttes de pluie sur un pare-brise et dispositif d'aide à la conduite (2010) (0)
Mise au point Effets cutanés des nouvelles molécules utilisées en cancérologie New drugs in oncology and skin toxicity (2009) (0)
Traitement des récidives des sarcomes rétro-péritonéaux : Dossier thématique : Récidives locorégionales : un défi thérapeutique (2004) (0)
Efficacité et tolérance du sonidégib 200 mg chez des patients atteints d’un carcinome basocellulaire localement avancé (CBCla) évalué selon des critères de type RECIST appliqués au CBC : analyse finale à 42 mois de l’étude BOLT (2019) (0)
AnalysisofDermatologic Events inVemurafenib-TreatedPatients WithMelanoma (2013) (0)
P215 - Dermatose neutrophilique associée à un mycosis fongoïde purpurique pilotrope chez un patient présentant également un lymphome folliculaire B (2005) (0)
Les anticorps anti-PD-1 et anti-PD-L1 dans le mélanome et le cancer bronchique (2017) (0)
Détection de la maladie micrométastatique résiduelle du mélanome : le rôle du ganglion sentinelle (2014) (0)
Abstract B10: Inhibiting eIF4F-mediated adaptive translatome reprogramming is a salvage strategy for targted melanoma therapy (2017) (0)
L’ipilimumab dans la vraie vie : étude prospective d’une cohorte de 79 patients traités en programme compassionnel (2011) (0)
Données de survie globale de l’étude COLUMBUS, étude de phase III avec encorafénib (ENCO) plus binimétinib (BINI) versus vémurafénib (VEM) ou encorafénib (ENCO) dans le mélanome métastatique BRAF muté (2018) (0)
Profils des réponses et des rechutes des patients traités par vemurafenib pour un mélanome métastatique (2013) (0)
Survie Globale (SG) à cinq ans dans l’étude COLUMBUS : un essai randomisé de phase 3 évaluant encorafénib plus binimétinib versus vémurafenib ou encorafénib chez les patients atteints d’un mélanome muté BRAF V600 (2021) (0)
Histiocytose métabolique ou xanthomatose hyperlipémique : pourquoi chercher les causes compliquées quand elles sont simples ? (2012) (0)
Application des tétramères à la détection in situ de lymphocytes T clonotypiques anti-Melan A/Mart-1 26-35 dans les mélanomes cutanés régressifs (2008) (0)
Vitiligo induit par traitement anti-PD-1 : un signe associé à la réponse antitumorale ? (2013) (0)
Optimisation de la relation entre les ventes et le marketing (2019) (0)
Dosimetric impact of an AI-based delineation software satisfying international guidelines in breast cancer radiotherapy (2020) (0)
Ipilimumab en pratique quotidienne dans le mélanome métastatique : les taux d’éosinophiles et de lymphocytes après une cure sont associés à une meilleure réponse au traitement (2012) (0)
Transmission de données sur un canal en duplex temporel (1990) (0)
Tenofovir-induced osteoporosis fracture in a patient using PrEP: A pitfall for the oncologist. (2023) (0)
Vemurafenib et radio-sensibilisation (2012) (0)
[Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma]. (2017) (0)
Érythème polymorphe photodistribué induit par le vandetanib : trois cas (2011) (0)
Rapid and objective CT-scan prognostic scoring identifies patients with long-term clinical benefit on phase I trials (2016) (0)
Unlocking the Potential of Immuno-Oncology in Advanced Cutaneous Squamous Cell Carcinoma : Role of Checkpoint Blockade (2019) (0)
1226PDFive-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma (2017) (0)
3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM) (2015) (0)
Frequency and current management of erlotinib-related skin effects (2008) (0)
PO-0807: Diversity of PET imaging biomarkers predicting cervical cancer treatment outcome: where do we stand? (2018) (0)
Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials (2016) (0)
130 INVITED TKI's, BRAF Inhibitors and the Problem of New Toxicities Such as Keratoacanthoma and Induction of Invasive SCC (2011) (0)
EP-1692: Multi-device textural analysis on 18F-FDG PET images for predicting cervical cancer recurrence (2017) (0)
Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo (2019) (0)
3350 Mx1 incomplete loss in primary ulcerated melanoma: An observation that may help explain IFNa sensitivity of ulcerated melanoma? (2015) (0)
126OA phase I study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of AL3810 in advanced solid tumors (2015) (0)
A randomized, open label, multicenter comparative phase II trial of ipilimumab after isolated limb perfusion (ILP), versus ILP alone in patients with in-transit metastases melanoma stage IIIB and IIIC. (2015) (0)
Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials (2016) (0)
27. Harmonization of 18F-FDG PET images for multicenter radiomic studies (2017) (0)
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]. (2021) (0)
Abstract A051: Prediction of clinical outcomes of cancer patients treated with anti-PD-1/PD-L1 using a radiomics-based imaging score of immune infiltrate (2018) (0)
EP-1993: Evaluation of the pertinence of CT-based radiomics shape features with 3D printed phantoms (2018) (0)
EP-2100: Development of a filter-based method for multicenter PET image harmonization in radiomic studies (2018) (0)
Gene expression profiling of sequential tumor biopsies is a powerful approach to identify putative biomarkers of therapeutic benefit in a phase I study combining sorafenib and dacarbazine (2007) (0)
Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma (2023) (0)
Detailed safety profile of the anti-PD-1 monoclonal antibody pembrolizumab in 78 consecutive patients (pts) with advanced melanoma (2016) (0)
Is depression associated with more emergency visits in inflammatory bowel disease ? (2014) (0)
PD-0425: Radiomics for selection of patients treated with immuno-radiotherapy: pooled analysis from 6 studies (2020) (0)
OC-0075: A MRI radiomic signature for predicting brachytherapy outcomes in locally advanced cervical cancer (2018) (0)
Cancer Gene Profiling through Unsupervised Discovery (2021) (0)
EP-1875: Correlation between MRI-based hyper-perfused areas and tumor recurrence in high-grade gliomas (2016) (0)
Clear cell sarcoma (CCS) or malignant melanoma of soft parts: A retrospective clinicopathologic study of 52 cases (2008) (0)
1249 POSTER Cutaneous Manifestations of Selumetinib, a New MEK Inhibitor (2011) (0)
1254PTolerance and outcomes of stereotactic radiosurgery combined with anti-PD1 (pembrolizumab) for melanoma brain metastases (2017) (0)
Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis. (2018) (0)
OC-0681: Deep learning auto contouring of OAR for HN radiotherapy: a blinded evaluation by clinical experts (2020) (0)
Phase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma: Looking for predictive markers of efficacy. (2010) (0)
Medical image computing to assess tumor infiltrating CD8 T cells, tumor immune phenotype and response to anti-PD-1/PD-L1 immunotherapy in prospective phase 1 trials. (2018) (0)
[Systemic treatment of melanoma brain metastases]. (2015) (0)
Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i (2020) (0)
[Perineal giant cell fibroblastoma in a five years old boy managed with micrographic surgery and local reconstruction with a posterior perforator thigh flap]. (2009) (0)
Analysis of the impact of rCBV map threshold to predict tumor recurrence in high-grade gliomas (2016) (0)
28 An MRI radiomic signature for predicting brachytherapy outcomes in locally advanced cervical cancer (2018) (0)
Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials (2019) (0)
Relation between baseline LDH and tumor burden in advanced melanoma in two phase III trials of oblimersen-dacarbazine (OBL-DTIC) versus DTIC. (2010) (0)
9300 ORAL Dramatic Efficacy of Neoadjuvant Therapy by the Association Cisplatin, Fluorouracil and Cetuximab in Locally Advanced Non Resectable Epidermoid Skin Carcinoma (2011) (0)
PO-1227: A dose escalation phase 1 study of radiotherapy combined with ipilimumab in metastatic melanoma. (2020) (0)
Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma. (2021) (0)
OC-0586 Immunological contexture basis of a prognostic radiomics signature in head and neck cancers (2019) (0)
BraTS 2020 challenge solution : Brain tumor segmentation with self-ensembled , deeply-supervised 3 D-Unet like neural networks (2020) (0)
Expanding the Boundaries : Update in Nuclear Cardiology (2004) (0)
An advanced tumor shape radiomic signature predicts recurrence of locally advanced (LA) HNSCC patients (pts) (2016) (0)
2876 Radiomics feature quantification in patients with locally advanced head and neck carcinomas treated with chemoradiotherapy (2015) (0)
Abstract IA29: Role of eIF4F in anticancer drug resistance (2017) (0)
A Score Combining SUV peak of the Primary Tumor Computed on Pretreatment FDG-PET Scans and Neutrophilia Predicts Outcome in Locally Advanced Cervical Cancer (2017) (0)
Schema d'administration du n- hydroxy - 4 - {2- [3- (n, n- dimethylaminomethyl) benzofuran- 2 - ylcarbonylamino] ethoxy} benzamide (2012) (0)
PO-0628: Correlation between 18F-FDOPA uptake and tumor relapse in recurrent high-grade gliomas (2017) (0)
[New calculation algorithms in brachytherapy for iridium 192 treatments]. (2018) (0)
PCN113 TREATMENT PATTERNS AND OUTCOMES IN THE FRENCH COHORT OF PATIENTS WITH UNRESECTABLE STAGE III OR STAGE IV MELANOMA (MELODY STUDY): A RETROSPECTIVE LONGITUDINAL SURVEY (2010) (0)
Mycobacterium ahvazicum sp. nov., the nineteenth species of the Mycobacterium simiae complex (2018) (0)
S2 Meal Planning and Delivery (2019) (0)
Whole-genome assembly of Akkermansia muciniphila sequenced directly from human stool (2015) (0)
Alistipes ihumii (2014) (0)
Complete genome sequence of Courdo11 virus, a member of the family Mimiviridae (2013) (0)
Management of adverse skin reactions to anticancer agents: The Gustave Roussy Institute experience. (2009) (0)
Conditional Suicide SystemofEscherichia coli Released into SoilThatUsestheBacillus subtilis sacBGene (1993) (0)
Oceanobacillus timonensis sp. nov. and Oceanobacillus senegalensis sp. nov., two new moderately halophilic, Gram-stain positive bacteria isolated from stools sample of healthy young Senegalese (2018) (0)
Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure (2017) (0)
Pan-genomic analysis to redefine species and subspecies based on quantum discontinuous variation: the Klebsiella paradigm (2015) (0)
Non-contiguous finished genome sequence of Corynebacterium timonense type strain 5401744T (2014) (0)
Repertoire of the gut microbiota from stomach to colon using culturomics and next-generation sequencing (2018) (0)
Abstract A23: eIF4F is a key and targetable convergence nexus of multiple mechanisms of resistance to anti-BRAF and anti-MEK cancer therapies (2015) (0)
Draft genome of Gemmata massiliana sp. nov, a water-borne Planctomycetes species exhibiting two variants (2015) (0)
Draft Genome Sequence of Mycobacterium asiaticum Strain DSM 44297 (2014) (0)
Dermatologic Manifestations of Systemic Oncologic Therapy of Cutaneous Malignancies (2011) (0)
Consultant Oral Session Abstracts (2018) (0)
Detection of novel RNA viruses from free-living gorillas, Republic of the Congo: genetic diversity of picobirnaviruses (2018) (0)
Bariatric surgery in a patient treated with targeted therapies for metastatic melanoma: a case report. (2020) (0)
Hematologic Toxicities of Apparent Immune-Related Origins (2019) (0)
Draft Genome Sequence of Mycobacterium triplex DSM 44626 (2014) (0)
[How to announce the diagnosis for melanoma?]. (2014) (0)
Draft Genome Sequence of Mycobacterium cosmeticum DSM 44829 (2014) (0)
Hypodermal metastasis of malignant melanoma to the cheek. (2014) (0)
Risungbinella massiliensis sp. nov., a new member of Thermoactinomycetaceae isolated from human gut (2016) (0)
Draft Genome Sequence of Mycobacterium neworleansense Strain ATCC 49404T (2015) (0)
Draft Genome and Description of Eisenbergiella massiliensis Strain AT11T: A New Species Isolated from Human Feces After Bariatric Surgery (2018) (0)
Draft Genome Sequence of Mycobacterium mucogenicum Strain CSUR P 2099 (2015) (0)
Genome Sequence of Legionella massiliensis, Isolated from a Cooling Tower Water Sample (2014) (0)
86 Real time genome sequencing to decipher the molecular mechanism of resistance of Chryseobacterium oranimense, anew multidrug resistant species isolated from a cystic fibrosis patient (2013) (0)
Gut Microbiota Gram-Negative Populations in the Human Molecular Studies Neglect Apparently (2013) (0)
The proof of concept that culturomics can be superior to metagenomics to study atypical stool samples (2013) (0)
Draft Genome Sequence of Mycobacterium europaeum Strain CSUR P1344 (2015) (0)
PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma (2020) (0)
Sediminibacillus massiliensis sp. nov., a moderately halophilic, Gram-positive bacterium isolated from a stool sample of a young Senegalese man (2018) (0)
Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample (2013) (0)
Non-contiguous finished genome sequence and description of Clostridium saudii sp. nov (2014) (0)
Abstract 4282: Total RNA sequencing of frozen biopsies combined to k-mer sequence analysis identify new hallmarks of immune checkpoint therapy response in melanoma (2023) (0)
High-quality genome sequence and description of Bacillus dielmoensis strain FF4T sp. nov. (2015) (0)
Prevotella timonensis (2020) (0)
Draft Genome Sequence of Mycobacterium interjectum Strain ATCC 51457T (2016) (0)
The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics (2013) (0)
Ancillary evaluation of systemic immune antitumour response (SIAR) and tumour growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase I study Mel-Ipi-Rx (2019) (0)
[Immune checkpoint inhibitors for treatment of advanced stage melanoma]. (2020) (0)
Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma. (2021) (0)
Noncontiguous fi nished genome sequence and description of Nocardioides massiliensis sp . nov . GD 13 (2016) (0)
Genome sequence of Oceanobacillus picturae strain S1, an halophilic bacterium first isolated in human gut (2015) (0)
Bibliothèque de l'école (2012) (0)
lecture par Lydia (2012) (0)
Application Domains - Environnement (2002) (0)
Colza: diminuer les insecticides, c'est possible (2017) (0)
Accompagner le jeune enfant dans sa découverte du monde (2019) (0)
Mensurations et niveau de qualification des chevaux d'endurance de race Arabe et croisé Arabe inclus dans le projet GenEndurance 2011 (2012) (0)
[Immunotherapy for melanoma: how can tolerance be overcome?]. (2001) (0)
G1 Le monde, les continents, les océans (2012) (0)
lecture par Subha (2012) (0)
with hemangioblastic characteristics Identification of human chronic myelogenous leukemia progenitor cells (2012) (0)
Hybridation de méthodes d'assimilation de données séquentielle et variationnelle de rang réduit dans l'océan Pacifique Tropical (2006) (0)
[Misleading and rare form of vulvar carcinoma with fast development. Suspicion of human papillomavirus infection]. (1990) (0)
NON-MELANOMA SKIN CANCER MORTALITY IN KIDNEY TRANSPLANT RECIPIENTS (2015) (0)
la sortie vélo (2013) (0)
[Treating metastatic melanoma: Risk management]. (2017) (0)
lecture par Matis (2012) (0)
Anagrammes par Tony (2012) (0)
Etude de la locomotion du cheval par accéléromètrie, électromyographie de surface et cinématique (2003) (0)
Évaluation et prévision du risque lié aux populations de limaces nuisibles aux grandes cultures : constitution d’un réseau expérimental permettant de comprendre l’impact des pratiques agricoles et des facteurs environnementaux (RESOLIM) (2018) (0)
Abscopal anti-tumor effect in a patient with melanoma and COVID-19 (2021) (0)
lecture par Subhalakshmi (2012) (0)
Comparaison de deux stratégies de dépistage des troubles nutritionnels en MCO (2017) (0)
H5 LES CHATEAUX FORTS (2013) (0)
La démarche mentale lors du diagnostic (2007) (0)
PERCEPTION DU RISQUE CARDIOVASCULAIRE : LES PATIENTS QUI SOUFFRENT DE SCHIZOPHRENIE SONT COMME LES AUTRES (2021) (0)
À propos de l’expertise collective de l’Inserm sur la fibromyalgie de l’adulte et de l’enfant (2021) (0)
Maintien et surveillance d'un insuffisant respiratoire à domicile. Rôle du technicien. (1984) (0)
LES SARCOÏDES DES ÉQUIDÉS : ÉTUDE BIBLIOGRAPHIQUE ET ÉTUDE RÉTROSPECTIVE DE L'EFFICACITÉ DE LA POMMADE SELEKT XXTERRA. (2008) (0)
リモート・ダイレクト・ストレージ・アクセス (2011) (0)
Identification ofHumanHerpesvirus 6Variants A andB byAmplimer Hybridization withVariant-Specific Oligonucleotides and Amplification withVariant-Specific Primers (1994) (0)
lecture par Inas (2012) (0)
La durée de la peine (1988) (0)
Elections délégués de la classe (2013) (0)
Colza: preserver les auxiliaires qui regulent les ravageurs (2013) (0)
Conseil de lecture par Elisa (2012) (0)
Peptide Presentation and Multifunctional Tract Model: Correlation with MHC Class II Protective Immunity in a Murine Genital Induces Different Levels of muridarum Chlamydia Immunization with Live and Dead (2011) (0)
L'oeil du loup par Lydia (2013) (0)
Uncoupling from transcription protects polyadenylation site cleavage from inhibition by DNA damage (2022) (0)
New Results - Assimilation de données en océanographie (2002) (0)
Identification et optimisation de systèmes en physique et en environnement (2002) (0)
The majority of peripheral blood leukocytes use the P-selectin glycoprotein ligand (PSGL-1) as the major protein scaffold for cutaneous lymphocyte associated antigen (CLA) (1998) (0)
Post‐transcriptional polyadenylation site cleavage maintains 3′‐end processing upon DNA damage (2023) (0)
P5.02Development of Novel Anticancer Agents that Target Prohibitins and the Translation Initiation Factor eIF4A (2015) (0)
CD4 regulatory T cells inhibit natural killer cell functions in a transforming growth factor– (cid:1) –dependent manner (2005) (0)
Mesure de la respiration musculaire par respirométrie à haute résolution (2011) (0)
Altises d'hiver et colza: des infestations à gérer à l'automne (2015) (0)
Réunion de famille par Ambre (2012) (0)
Blood dendritic cells tether and roll on E- and P-selectin in non inflamed murine skin endothelium: A new perspective on skin immunosurveillance (1998) (0)
Blood dendritic cells exhibit highly efficient, PSGL-1 mediated tethering and rolling on E and P selectins in vitro and in vivo: A new perspective on immunosurveillance (1998) (0)
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? (2017) (0)
Je raconte un moment agréable de mes vacances par Bilal (2013) (0)
lecture par Ambre (2012) (0)
H1 Les grandes découvertes (2013) (0)
Homing receptors: potential therapeutical tools? (2002) (0)
Colza et abeilles : exposé de la problématique et mise en place d’un dispositif de vigilance sur les ruchers en région Centre (2011) (0)
eIF4F translation initiation complex, a predictive marker of response to immunotherapy in mucosal melanoma. (2023) (0)
Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8+ T lymphocyte emergence (2013) (0)
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma (2018) (0)
H 4 La vie quotidienne au Moyen Age (2012) (0)
Techniques de détection du VIH dans les milieux biologiques: Application à la recherche du virus dans le sperme (1994) (0)
La microbiopsie musculaire : un nouvel outil pour le suivi sportif et la détection précoce des dysfonctions musculaires (2010) (0)
lecture par Lilou (2012) (0)
H3 Naissance et expansion de l'Islam (2012) (0)
608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) (2022) (0)
Association of baseline corticosteroid treatment with outcomes for patients (pts) with BRAF-mutant melanoma brain metastases (MBMs) in COMBI-MB treated with dabrafenib and trametinib (DT). (2022) (0)
Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study (2022) (0)
Abstract CT109: Radiomic features in tumor assessment, preliminary results from a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with anti PD1 refractory melanoma (2022) (0)
Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases. (2022) (0)
Ravageurs du colza: La France rattrapée par les résistances (2016) (0)
La séance habillée (2012) (0)
Clinical significance of immune-related creatine phosphokinase increase associated with anti PD1/PD-L1 immunotherapies (2019) (0)
Abstract CT107: Correlation of biomarkers and clinical benefit of intratumoral BO112 and pembrolizumab in patients with anti PD1 refractory melanoma (2022) (0)
Anagrammes par Sorona (2012) (0)
1075P Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma (2021) (0)
Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor (2013) (0)
Dégâts d'oiseaux: une essentielle collecte de données (2017) (0)
Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up (2023) (0)
COLEOTOOL - Développement d’outils moléculaires en vue d’identifier les principaux charançons ravageurs du colza et leurs auxiliaires parasitoïdes. (2019) (0)
26198 Evaluating patient outcomes in the BOLT 42-month trial using modified Response Evaluation Criteria in Solid Tumors methodology: Results from a preplanned analysis (2021) (0)
Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study (2022) (0)
Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD. (2022) (0)
Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study (2019) (0)
Melanoma and immunotherapy bridge 2015 (2016) (0)
DOUBROVSKI S'EST ENFUI A L'ETRANGER (1999) (0)
Ma rentrée par Lina (2012) (0)
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors. (2022) (0)
Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks (2022) (0)
1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program (2021) (0)
The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021 (2022) (0)
Insectes d'automne. La protection du colza se complexifie (2012) (0)
Tsiganes et voyageurs : Pour une définition contextualisée de la précarité (1999) (0)
Ma rentrée par Jade (2012) (0)
Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis (2021) (0)
Epidémiosurveillance: vers un meilleur ciblage des traitements (2015) (0)
Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma (2023) (0)
Comment je fais une cimentoplastie de l’acétabulum : abord de l’épine iliaque antéro-inférieure (2022) (0)
Réseaux de neurones et électroencéphalogramme : fructueuse association (2002) (0)
Lecture par Stéphane (2012) (0)
G3 Les reliefs et les fleuves en France (2012) (0)
Sarcoidosis reactivation with immune checkpoint inhibitors (2020) (0)
Effect de l'entraînement sur la fonction mitochondriale musculaire du cheval d'endurance (2009) (0)
Variations physiologiques des paramètres sanguins chez le cheval d’endurance de haut niveau lors de séances de galop sur piste (2010) (0)
Limiter le risque de resistance aux pyrethrinoides (2014) (0)
Gestion alternative des ravageurs en grandes cultures : la démarche territoriale innovante d’un collectif d’agriculteurs avec le projet R2D2 (2021) (0)
Phase I study of Androgen deprivation therapy in combination with anti-PD-1 in patients pre- treated with anti-PD-1. (2022) (0)
1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma (2021) (0)
Abstract 1251: Low plasma Arginine level is associated with resistance to immune checkpoint blockers in patients with advanced cancer (2022) (0)
G4 LES CLIMATS EN FRANCE (2013) (0)
[Use of genome-wide testing in oncology: French expert opinion based on the Delphi methodology]. (2023) (0)
Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma (2023) (0)
[Treatment of melanoma with immune checkpoints inhibitors]. (2021) (0)
Abstract 2009: Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma (2020) (0)
Management of Melanoma Brain Metastasis (2019) (0)
S09 03 MA – ONCOGENE ACTIVATION IN ULTRAVIOLET-INDUCED SKIN TUMORS FROM NORMAL INDIVIDUALS AND XERODERMA PIGMENTOSUM PATIENTS (1991) (0)
23. Monoclonal Antibodies (2013) (0)
The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021 (2022) (0)
Real-world data on antiviral treatments for hepatitis C virus infections: Can we deﬁne intention to treat or per protocol analyses? (2018) (0)
P361 Risk of persistent gastrointestinal inflammation after treatment with immune checkpoint inhibitors (2023) (0)
Modes of action of ipilimumab and biomarkers of resistance to therapy in patients (2013) (0)
Mo1318 Ipilimumab Colitis: A GETAID Multicentric Study (2013) (0)
EORTC Melanoma Group achievements (2012) (0)
Effect of BRAF Mutation Status on Efficacy of nab-Paclitaxel versus Dacarbazine in Chemotherapy-Naive Patients with Metastatic Melanoma Treated in a Phase III Trsial (2013) (0)
Complete responders to checkpoint inhibitors in advanced melanoma: Relapse risk factors, and patients' outcomes. (2021) (0)
[Detection of residual microscopic disease in melanoma: interest of the sentinel lymph node procedure?]. (2014) (0)
Melanoma Group achievements (2012) (0)
Reply to E. Hindié. (2021) (0)
Place of steroids and prognosis factors for grade = 3 immune-checkpoint inhibitors induced hepatitis: a 6-year prospective study (2022) (0)
[What is new in oncodermatology?]. (2008) (0)
Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies (2018) (0)
Comparison of sun protection modalities in parents and children. (2012) (0)
CMET-21. TOLERANCE AND OUTCOMES OF STEREOTACTIC RADIOSURGERY COMBINED WITH ANTI-PD1 (PEMBROLIZUMAB) FOR MELANOMA BRAIN METASTASES (2017) (0)
Draft Genome Sequence of Mycobacterium colombiense (2017) (0)
Nail Abnormalities in Oncology Practice (2013) (0)
89INSKIN TOXICITY. (2014) (0)
Changes in microRNAs spectrum during melanoma progression (2006) (0)
Chapter 17 Immunotherapy of Melanoma: A New Era (2011) (0)
1139P Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma (2020) (0)
Prognostic and predictive value of metformin in the EORTC 1325/KEYNOTE- 054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma (2023) (0)
Concerning the article by Louveau et al “Clinical value of early detection of circulating tumour DNA BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor” (2017) (0)
788 A phase 1b study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of neoadjuvant use of PH-762 administered intratumorally in subjects with advanced melanoma (2022) (0)
Discovery of Iminobenzimidazole Derivatives as Novel Cytotoxic Agents (2018) (0)
Dermatologic Side Effects of Systemic Targeted Anticancer Therapy (2018) (0)
Combining tumor destruction by electrochemotherapy and innate immunity by CpG-ODN: Toward a new combination treatment for melanoma with skin metastases. (2006) (0)
[New treatments for metastatic melanoma: a first hope]. (2011) (0)
Skin side effects targeted anti-EGFR and anti-BRAF therapies (2013) (0)
26200 Tumor burden in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma following treatment with sonidegib: Results of the 42-month BOLT study (2021) (0)
Contemporary Evaluation of Acute Chest Pain (2019) (0)
Importance du partenariat entre un centre de lutte antituberculeuse (CLAT) et le département dans le dépistage systématique de la tuberculose chez les mineurs non accompagnés (MNA) (2018) (0)
Immunothérapie du mélanome: comment rompre la tolérance? (2001) (0)
Comment les nouvelles technologies changent la façon dont les enfants se divertissent (2015) (0)
Beat generation, beat cinéma : la contre-culture cinématographique au regard des auteurs de la Beat generation et de leurs empreintes dans le cinéma contemporain / Cédric Robert (2015) (0)
Beat generation, beat cinéma : la contre-culture cinématographique au regard des auteurs de la Beat generation et de leurs empreintes dans le cinéma contemporain / Cédric Robert (2015) (0)
Raccordements de bandes et profils de constantes diélectriques pour des hétérostructures 2D à semiconducteurs (2013) (0)
Complexité du dépistage de la tuberculose maladie chez les migrants primo-arrivants non-stabilisés (2019) (0)
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study (2020) (0)
Boîtes quantiques semi-conductrices : relation entre morphologie, structure électronique et propriétés optiques (2013) (0)
Intégration optique par croissance directe de nanostructures III-V sur silicium (2013) (0)
Développement d'un laser sur silicium dans l'approche pseudomorphique (2012) (0)
Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma (2014) (0)
Leukocyte trafficking in the skin. (2002) (0)
Molecular testing in Cutaneous Melanoma (2014) (0)
Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients (2023) (0)
Mitochondrial myopathy associated with anti-programmed cell death 1 therapy. (2019) (0)
Adaptation d’un centre de lutte antituberculeuse (CLAT) aux évolutions des contextes législatifs et migratoires entre 2012 et 2016 (2017) (0)
Développement de nanostructures sur silicium pour l'émission laser à grande longueur d'onde (2011) (0)
Intégration pseudomorphique dans la filière GaP/Si pour les applications lasers sur puce (2014) (0)
Quelles pratiques de diagnostic et de prise en charge des séquelles de tuberculose pulmonaire chez les migrants primo-arrivants dans un CLAT ? (2020) (0)
Immunopharmacology of cancer vaccines: Restoration of NKG2D levels and functions in metastatic melanoma treated with exosomes. (2006) (0)
Patient with Systemie (0)
Undifferentiated Neuroblastoma : Extremely Rare and Unfavorable Subtype of Neuroblastoma (2001) (0)
Is earlier better for melanoma checkpoint blockade? (2018) (0)
Gastric biopsy from patient 2 is infiltrated by a poorly differentiated adenocarcinoma with signet r (2011) (0)
Abstract A192: PK/PD modeling-based optimization of administration schedule for the histone deacetylase inhibitor (HDACi) S78454/PCI-24781 in phase I. (2011) (0)
Endoscopic view of antral polyps in patient 1, biopsies of which confirmed signet-ring adenocarcinom (2011) (0)
An invasive adenocarcinoma is present in the gastrectomy specimen from patient 1 (2011) (0)
CT abdomen with oral contrast in patient 2 demonstrating thickening below the oesophagogastric junct (2011) (0)
Dermatose neutrophilique chez un patient traité par ipilimumab pour un mélanome métastatique (2011) (0)
Description d'un réseau informel de soins primaires au sein d’un désert médical : exemple du cirque de Mafate (La Réunion) (2017) (0)
Carcinomes basocellulaires localement avancés traités par vismodégib : devenir des rémissions complètes après arrêt du traitement (2017) (0)
Archéologie aérienne aussi au Grand-Duché de Luxembourg (1988) (0)
Mélanomes sans primitif connu, étude rétrospective de 58 cas (2013) (0)
Éruption cutanée peu spécifique révélant un lupus cutané subaigu induit par nivolumab (2022) (0)
Le carcinome de Merkel : état des lieux du réseau CARADERM en 2020 (2020) (0)
Carcinomes basocellulaires (CBC) avancés nécessitant un traitement systémique : état des lieux du réseau CARADERM (2018) (0)
Myo-fasciite chez un patient traité par inhibiteur de checkpoint pour un mélanome adjuvant (2022) (0)
Cytopathie mitochondriale lors d’un traitement par nivolumab pour un mélanome stade IV (2016) (0)
44 Assessing the impact of key preprocessing concepts on the pseudo CT generation (2019) (0)
Séquençage systématique d’un panel de gènes fréquemment mutés dans le mélanome : vers une médecine personnalisée ? (2013) (0)
Mélanome osseux primitif : une nouvelle entité ? (2011) (0)
Une hémophilie acquise à l’ipilimumab (2011) (0)
Progression de tumeurs préexistantes induite par le vémurafénib (2014) (0)
BRAF, MEK Inhibition Shows Strong Long-Term Survival Benefit in Melanoma (2016) (0)
Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma. (2022) (0)
Politiques de formation (1994) (0)
Strategies européennes pour la television interactive: le club d'investissement media (1994) (0)
Profil évolutif des réponses et progressions tumorales chez 15 patients traités par inhibiteurs de BRAF (2011) (0)
Nouveaux algorithmes de calcul en curiethérapie pour les traitements par iridium 192 (2018) (0)
Colites auto-immunes sous ipilimumab : aspects anatomopathologiques (2011) (0)
Résultats carcinologiques des 109 perfusions de membre isolé sous circulation extracorporelle (PMI-CEC) pour le traitement des métastases en transit des mélanomes (MTM) (2011) (0)
Quatre réponses spectaculaires à un anticorps anti-CTLA-4 après progression initiale sous traitement (2011) (0)
The Dendritic Cell: The Immune System's Adjuvant-A Strategy To Develop a HCV Vaccine? (2006) (0)
Traitement des patients atteints d’un mélanome métastatique cérébral par ipilimumab à haute dose et radiochirurgie : résultats à 5 ans (2020) (0)
Cytologie échoguidée en oncodermatologie : des implications diagnostiques et thérapeutiques (2014) (0)
Ipilimumab combiné à une radiochirurgie-stéréotaxique chez des patients porteurs d’un mélanome avec métastases cérébrales. Une étude de phase 2, multicentrique, ouverte (2018) (0)
Utilisation de l'analgésie locorégionale chez le traumatisé thoracique sous ventilation mécanique : une étude préliminaire (2020) (0)
Essai multicentrique, ouvert et randomisé de phase III (BRIM3) évaluant vemurafenib (V) vs dacarbazine (D) dans le mélanome muté BRAFV600E (2011) (0)
Dermatose cutanéomuqueuse lichénoïde érosive sévère après vaccination par ChAdOx1-S révélant une maladie de Castleman (2022) (0)
Éruption de kératoses séborrhéiques sous dabrafénib et tramétinib (2022) (0)
Ischémie digitale sous irinotécan et capécitabine (2022) (0)
Ne pas être uniciste en médecine (2011) (0)
Tolérance de la radiothérapie stéréotaxique cérébrale chez les patients traités par pembrolizumab pour un mélanome métastatique (2016) (0)
Tolérance et effets indésirables de l’anticorps monoclonal MK-3475 chez les patients atteints de mélanome avancé (2014) (0)
Circonstances diagnostiques des mélanomes vulvaires et vaginaux (2016) (0)
Efficacité du trametinib (T), sur la survie sans progression (SSP) et la survie globale (SG), en comparaison à la chimiothérapie (C) chez des patients (pts) ayant un mélanome métastatique (MM) avec mutation de BRAFV600E/K (2012) (0)
Computed Tomography in the Diagnosis, Staging, and Management of Abdominal Lymphoma (1977) (0)
Comparaison du profil mutationnel somatique de métastases de mélanome avant traitement et après résistance au vémurafénib (2014) (0)
Rémission complète d’un carcinome de Merkel du membre inférieur droit après traitement par électrochimiothérapie (2012) (0)
Imagerie Compton en protonthérapie : de la simulation GATE à la reconstruction d'images (2013) (0)
Isoformes 1 et 4 du LDH plasmatique comme biomarqueurs pronostiques et de réponse au traitement dans le mélanome (2022) (0)
LES DEVELOPPEMENTS TECHNIQUES POUR LA GESTION DES CHAUSSEES (1996) (0)
Carcinome de Merkel : état des lieux du réseau CARADERM (2018) (0)
Répondeurs complets sous immunothérapie et thérapie ciblée dans le mélanome avancé (2017) (0)
Specific CTL Induce Cross-Recognition and Elimination by Autologous Endothelial and Tumor Cells Gap Junction Communication between (2009) (0)
Kératoacanthome à développement endophytique : une tumeur rare de diagnostic difficile (2022) (0)
Suivi de 7 patients traités par infliximab pour une colite corticorésistante induite par l’ipilimumab dans le cadre d’un mélanome métastatique (2014) (0)
Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients. (2021) (0)
Connaissance et attitude de la population française sur le diagnostic du mélanome et sa prévention en 2011 (2012) (0)
Etude d'une base de cas cliniques pour la construction d'un système expert d'aide au diagnostic des meningites infantiles (1990) (0)
76P Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials (2022) (0)
Abstract CCOS14-04: Resistance to anti-BRAF and anti-MEK agents: Lost in translation (2014) (0)
LBA44 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial (2022) (0)
LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma (2022) (0)
1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS (2020) (0)
806P Updated toxicity profile and relapse-free survival outcomes using an adapted pyrexia management algorithm in patients with resected stage III BRAF V600E/K-mutant melanoma treated with adjuvant dabrafenib plus trametinib in COMBI-APlus (2022) (0)
Personal melanoma risk awareness versus intrinsic risk. (2013) (0)
P366 Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI) (2018) (0)
Proteinuria, CrCl, and Immune Activation in Antiretroviral-Naïve HIV-Infected Subjects (2010) (0)
[Skin cancer: the time for therapeutic revolution!]. (2014) (0)
1137P Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study (2020) (0)
Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial (2018) (0)
813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study (2022) (0)
803P Patient-reported outcomes in patients with resected, stage III BRAF V600+ melanoma treated with adjuvant dabrafenib + trametinib: COMBI-APlus study (2022) (0)
1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma (2021) (0)
786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma (2022) (0)
885TiP The I-PACE study: Imgatuzumab in PAtients with advanCEd cutaneous squamous cell carcinoma (aCSCC) (2022) (0)
1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Caroline Robert?

Caroline Robert is affiliated with the following schools:

University of Sydney
University of Oxford
Université Paris Cité
Aix-Marseille University
McGill University
Yale University
Paris-Saclay University
Université du Québec
University of Louisville
Massachusetts Institute of Technology
University of Tübingen
Sorbonne University

Caroline Robert's Academic­Influence.com Rankings

Caroline Robert's Degrees

Why Is Caroline Robert Influential?

Caroline Robert's Published Works

Published Works

What Schools Are Affiliated With Caroline Robert?

Caroline Robert's AcademicInfluence.com Rankings